# 2025年11月3日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 从星火到燎原：一种ROS与光级联激活的近红外二区AIE探针用于精准肿瘤成像与自我放大光疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41176654](https://pubmed.ncbi.nlm.nih.gov/41176654)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41176654
**DOI：** 10.1002/advs.202514789

### 第一部分 原文与翻译

**英文原标题：** From Spark to Flame: ROS- and Light-Cascade Activatable NIR-II AIE Probe for Precise Tumor Imaging and Self-Amplifying Phototherapy.

**英文摘要原文：**
The development of photoactivatable theranostic probes represents a major focus in precision tumor therapy. However, those previously reported probes often suffer from limited photoresponsivity, short excitation/emission wavelengths, and inactivity in the absence of light, restricting their ability to precisely diagnose deep-seated tumors or enable effective phototherapy without auxiliary interventions. To address these challenges, this study designs a second near-infrared (NIR-II) aggregation-induced emission (AIE) theranostic probe based on a dihydroindole skeleton, featuring dual reactive oxygen species (ROS)- and NIR light-cascade activation. Upon ROS activation in the tumor microenvironment, TT-DHIn undergoes transformation into TT-In, exhibiting NIR-II fluorescence emission and photodynamic/photothermal therapy (PDT/PTT) capabilities, thereby serving as a photoactivatable "guiding radar" with an exceptional signal-to-background ratio. Following pre-activation, TT-In efficiently generates ROS under 660 nm laser irradiation, enabling self-supplementation of intratumor ROS. Furthermore, the intratumor TT-DHIn undergoes cyclic conversion into TT-In, significantly enhancing phototherapeutic efficacy and demonstrating potent in vitro cytotoxicity and in vivo tumor eradication. This dual-activatable cascade strategy synergistically integrates tumor biomarker (ROS) responsiveness with photoactivation, offering a promising platform for NIR-II imaging-guided precision phototheranostics with strong potential for clinical translation.

**中文摘要译文：**
光激活诊疗探针的开发是肿瘤精准治疗领域的一个主要焦点。然而，以往报道的探针常常存在光响应性有限、激发/发射波长较短以及在无光照时无活性等问题，这限制了它们在没有辅助干预的情况下精准诊断深部肿瘤或实现有效光疗的能力。为应对这些挑战，本研究设计了一种基于二氢吲哚骨架的近红外二区（NIR-II）聚集诱导发光（AIE）诊疗探针，其特点是具有活性氧（ROS）和近红外光级联双重激活功能。在肿瘤微环境中经ROS激活后，TT-DHIn转变为TT-In，展现出NIR-II荧光发射以及光动力/光热治疗（PDT/PTT）能力，从而作为一个具有优异信噪比的光激活“引导雷达”。预激活后，TT-In在660 nm激光照射下能高效产生活性氧，实现了肿瘤内ROS的自我补充。此外，肿瘤内的TT-DHIn会循环转化为TT-In，显著增强了光疗效果，并在体外细胞毒性实验和体内肿瘤根除实验中表现出强大效力。这种双重激活的级联策略将肿瘤生物标志物（ROS）响应性与光激活协同整合，为近红外二区成像引导的精准光诊疗学提供了一个极具临床转化潜力的平台。

### 第二部分 AI 大师评价

本研究旨在开发一种新型光激活诊疗探针，以克服传统探针在深层肿瘤诊疗中的局限性。研究者巧妙设计了一种基于活性氧（ROS）和近红外光级联激活的近红外二区（NIR-II）AIE探针，实现了从“星火”到“燎原”的信号及疗效放大。该探针首先被肿瘤微环境中的ROS激活以“点亮”肿瘤，随后通过光照进行自我放大的光动力与光热治疗。这项研究的创新之处在于其双重激活与级联放大机制，不仅提高了成像的精准度和信噪比，还实现了治疗效果的自我增强，为开发高效、精准的肿瘤光诊疗一体化策略提供了极具前景的新思路。

---

## 2. 双特异性抗体治疗复发/难治性多发性骨髓瘤期间的巨细胞病毒再激活

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41176584](https://pubmed.ncbi.nlm.nih.gov/41176584)
**期刊：** Blood cancer journal
**PMID：** 41176584
**DOI：** 10.1038/s41408-025-01393-8

### 第一部分 原文与翻译

**英文原标题：** Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究聚焦于接受双特异性抗体治疗的复发/难治性多发性骨髓瘤患者中巨细胞病毒（CMV）再激活的临床问题。从标题推断，该研究可能通过临床观察或数据分析，旨在揭示在这一前沿疗法背景下CMV再激活的发生率、风险因素及临床特征。这项研究具有重要的临床指导价值，因为它关注了新型免疫疗法带来的潜在感染风险，有助于优化患者的监测和预防策略。由于缺乏摘要，研究的具体设计和关键发现尚不明确，但其提出的问题对于确保治疗安全性至关重要。

---

## 3. 靶向Claudin 18.2免疫疗法的在靶/脱瘤毒性建模与应对

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41176582](https://pubmed.ncbi.nlm.nih.gov/41176582)
**期刊：** Nature communications
**PMID：** 41176582
**DOI：** 10.1038/s41467-025-65148-6

### 第一部分 原文与翻译

**英文原标题：** Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapies.

**英文摘要原文：**
Successfully extending immunotherapies to solid tumors involves addressing several key challenges, importantly the "antigen dilemma", the expression of a solid tumor target antigen on the normal tissue of tumor origin. Claudin 18.2 (CLDN18.2) has emerged as an important target for upper gastrointestinal (GI) cancer therapies (such as Zolbetuximab, a naked antibody, recently approved; or CT041, a second-generation chimeric antigen receptor (CAR) T cell therapy with promising clinical data). However, GI toxicities are reported from clinical use of both Zolbetuximab and CT041. Here, we describe clinical Zolbetuximab treatment associated cases of gastric erosive lesions. We also demonstrate and characterize on-target/off-tumor gastric toxicity targeting CLDN18.2 in a preclinical mouse model of CT041-scFv derived CAR T cell therapy. By developing CLDN18.2 fully-human VH-only single domain CARs, we demonstrate that on-target/off-tumor toxicity inversely correlates with affinity of the binder, and that a lower affinity CAR may widen the therapeutic window for CLDN18.2 by decreasing on-target/off-tumor toxicity while preserving efficacy.

**中文摘要译文：**
将免疫疗法成功应用于实体瘤涉及解决几个关键挑战，其中最重要的是‘抗原困境’，即实体瘤靶抗原在与其同源的正常组织上也有表达。Claudin 18.2 (CLDN18.2) 已成为上消化道 (GI) 癌症疗法的重要靶点（例如，近期获批的裸抗体Zolbetuximab；或具有良好临床数据的第二代嵌合抗原受体 (CAR) T细胞疗法CT041）。然而，Zolbetuximab和CT041的临床应用均有胃肠道毒性的报道。在此，我们描述了与Zolbetuximab临床治疗相关的胃糜烂性病变病例。我们还在一种源自CT041-scFv的CAR-T细胞疗法临床前小鼠模型中，展示并定性了靶向CLDN18.2的在靶/脱瘤胃毒性。通过开发仅含VH结构域的全人源CLDN18.2单域CAR，我们证明了在靶/脱瘤毒性与结合物的亲和力呈负相关，并且较低亲和力的CAR可能通过在保持疗效的同时降低在靶/脱瘤毒性，从而拓宽CLDN18.2靶向治疗的治疗窗口。

### 第二部分 AI 大师评价

本研究旨在解决靶向CLDN18.2免疫疗法中一个关键的临床难题——在靶/脱瘤毒性。研究者通过分析临床病例和构建临床前小鼠模型，证实了抗体药物Zolbetuximab和CAR-T疗法CT041均可引发胃部损伤。其核心创新在于，通过开发新型低亲和力全人源单域CAR-T，首次证明了降低CAR与靶点亲和力可以有效减轻在靶/脱瘤毒性，同时保留抗肿瘤活性。这一发现为优化CLDN18.2靶向CAR-T疗法提供了清晰的策略，即通过精细调控亲和力来拓宽治疗窗口，对开发更安全的实体瘤细胞免疫疗法具有重要的指导价值。

---

## 4. 冷冻消融联合信迪利单抗和仑伐替尼治疗晚期或转移性肝内胆管癌：一项2期临床试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41176543](https://pubmed.ncbi.nlm.nih.gov/41176543)
**期刊：** Nature cancer
**PMID：** 41176543
**DOI：** 10.1038/s43018-025-01058-2

### 第一部分 原文与翻译

**英文原标题：** Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 trial.

**英文摘要原文：**
Treatment options for advanced or metastatic intrahepatic cholangiocarcinoma (ICC) are limited. In this single-arm, phase 2 trial (CASTLE-01, NCT05010668 ), 28 participants with advanced or metastatic ICC who have progressed after chemotherapy were treated with cryoablation, followed by anti-PD1 sintilimab (200 mg every 3 weeks) plus lenvatinib (8-12 mg per day) 2 weeks later. The objective response rate assessed by Response Evaluation Criteria in Solid Tumors version 1.1 was 75.0% (95% confidence interval (CI): 59-91%), meeting the prespecified primary endpoint. Secondary endpoints of disease control rate, median progression-free survival and overall survival were respectively 100% (95% CI: 100-100%), 16.8 months (95% CI: 11.5-not reached (NR)) and 25.4 months (95% CI: 13.3-NR). Treatment was well tolerated. Post hoc multiomics analysis of paired pretreatment and on-treatment tumor biopsies suggested that cryoablation increased the tumor immunogenicity and dendritic cell activation, followed by triggering continuous replenishment of intratumoral CD8PD1 effectors from peripheral blood. The addition of lenvatinib transitioned endothelial cells into inflamed venules to boost lymphocyte influx and targeted tumor stroma to promote CD8PD1 effectors penetrating into tumor cell nests. Therefore, cryoablation combined with sintilimab plus lenvatinib represents a promising approach for the treatment of advanced or metastatic ICC. These findings also support the notion that cryoablation may trigger abscopal antitumor immunity in ICC when combined with lenvatinib and PD1 blockade. ClinicalTrials.gov registration: NCT05010668 .

**中文摘要译文：**
晚期或转移性肝内胆管癌（ICC）的治疗选择有限。在这项单臂、2期临床试验（CASTLE-01, NCT05010668）中，28名化疗后病情进展的晚期或转移性ICC参与者接受了冷冻消融治疗，并在2周后联用抗PD-1药物信迪利单抗（每3周200mg）和仑伐替尼（每日8-12mg）。根据实体瘤疗效评价标准1.1版评估，客观缓解率为75.0%（95%置信区间（CI）：59-91%），达到了预设的主要终点。次要终点方面，疾病控制率为100%（95% CI：100-100%），中位无进展生存期为16.8个月（95% CI：11.5-未达到（NR）），中位总生存期为25.4个月（95% CI：13.3-NR）。该治疗方案的耐受性良好。对治疗前后配对的肿瘤活检样本进行的事后多组学分析表明，冷冻消融增强了肿瘤的免疫原性和树突状细胞的活化，进而触发了外周血中的CD8+PD1+效应细胞向肿瘤内持续补充。仑伐替尼的加入将内皮细胞转化为炎性小静脉以促进淋巴细胞流入，并靶向肿瘤基质以促进CD8+PD1+效应细胞渗透到肿瘤细胞巢内。因此，冷冻消融联合信迪利单抗和仑伐替尼为晚期或转移性ICC的治疗提供了一种有前景的方法。这些发现也支持了在联合仑伐替尼和PD-1抑制剂时，冷冻消融可能在ICC中触发远隔抗肿瘤免疫效应的观点。ClinicalTrials.gov 注册号：NCT05010668。

### 第二部分 AI 大师评价

本研究旨在探索冷冻消融联合信迪利单抗（PD-1抑制剂）和仑伐替尼（多靶点抑制剂）治疗化疗失败的晚期肝内胆管癌的有效性和安全性。这项2期临床试验结果显示，该三联疗法取得了高达75%的客观缓解率和100%的疾病控制率，生存数据亦十分亮眼。该研究的创新性在于将局部物理消融与全身性免疫、靶向治疗相结合，并通过多组学分析揭示了其协同增效的免疫学机制。尽管是小样本单臂研究，但其为难治性肝内胆管癌提供了一种极具前景的治疗新策略，并为冷冻消融触发远隔效应提供了临床证据。

---

## 5. 戈菲妥单抗联合替雷利珠单抗治疗复发/难治性弥漫性大B细胞淋巴瘤：一项单中心探索性试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41176542](https://pubmed.ncbi.nlm.nih.gov/41176542)
**期刊：** Blood cancer journal
**PMID：** 41176542
**DOI：** 10.1038/s41408-025-01404-8

### 第一部分 原文与翻译

**英文原标题：** Glofitamab combined with tislelizumab in relapsed/refractory diffuse large B-cell lymphoma: a single-center pilot trial.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该研究旨在初步探索戈菲妥单抗（一种双特异性抗体）与替雷利珠单抗（一种PD-1抑制剂）联合方案，在治疗复发或难治性弥漫性大B细胞淋巴瘤中的疗效与安全性。这项研究作为一项单中心探索性试验，其创新之处在于将两种不同机制的免疫疗法相结合，可能协同增强抗肿瘤免疫反应。尽管研究规模有限，其结果可能为开发针对该类患者的无化疗新策略提供重要的早期临床证据和理论基础，但其结论尚需更大规模的多中心研究来验证。

---

## 6. 靶向claudin18.2的CAR-T细胞在临床前模型中的在靶脱瘤毒性研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41176533](https://pubmed.ncbi.nlm.nih.gov/41176533)
**期刊：** Nature communications
**PMID：** 41176533
**DOI：** 10.1038/s41467-025-61858-z

### 第一部分 原文与翻译

**英文原标题：** On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical models.

**英文摘要原文：**
Claudin 18.2 (CLDN18.2)-targeted CAR-T cell therapies have shown promising clinical efficacy in gastric cancer. However, early-phase trials have reported gastrointestinal adverse events due to on-target off-tumor recognition of CLDN18.2 in the gastric mucosa. By leveraging shared CLDN18.2 epitopes and expression in humans and mice, we establish an in vivo model that replicates the on-target off-tumor toxicity of CLDN18.2 CAR-T. Our findings confirm that this toxicity is independent of the CAR construct's design, co-stimulatory domain, and tumor model. Additionally, we demonstrate the utility of this model in testing strategies to mitigate on-target toxicity, such as Boolean-logic AND-gate approaches. Our results offer insights into the use of mouse models that recapitulate on-target off-tumor toxicities, with the caveat that although we are often concerned that models will undercall toxicities in humans, they may also overcall the incidence and severity of toxicities, prematurely discarding promising therapeutic agents from further clinical development.

**中文摘要译文：**
靶向Claudin 18.2 (CLDN18.2)的CAR-T细胞疗法在胃癌治疗中已显示出令人鼓舞的临床疗效。然而，早期临床试验报道了因CAR-T细胞在靶识别胃黏膜上的CLDN18.2而引起的胃肠道不良事件。通过利用人鼠间共享的CLDN18.2表位及其表达特性，我们建立了一种能够复现CLDN18.2 CAR-T在靶脱瘤毒性的体内模型。我们的研究结果证实，这种毒性与CAR构建体的设计、共刺激域以及肿瘤模型无关。此外，我们证明了该模型可用于测试缓解在靶毒性的策略，例如采用布尔逻辑“与门”策略。我们的研究结果为使用能重现在靶脱瘤毒性的小鼠模型提供了见解，但需注意一个警示：尽管我们常担心动物模型会低估在人体中的毒性，但它们也可能高估毒性的发生率和严重程度，从而导致有前景的治疗药物被过早地终止后续临床开发。

### 第二部分 AI 大师评价

本研究针对CLDN18.2 CAR-T疗法中关键的在靶脱瘤毒性问题，成功构建并验证了一个能稳定复现该毒性的临床前小鼠模型。研究的核心价值在于，它不仅证实了该毒性是靶点固有的，独立于CAR结构等因素，还提供了一个评估和优化CAR-T细胞安全策略（如“与门”逻辑）的实用平台。更具启发性的是，该研究警示我们，临床前模型在预测毒性时可能存在“高估”风险，这一洞见对于更审慎地解读临床前数据、避免过早放弃有潜力的疗法具有重要的指导意义。

---

## 7. 性与生殖健康及权利的部分进展：社会文化、行为、结构和技术变革对流行病学趋势的影响

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41176391](https://pubmed.ncbi.nlm.nih.gov/41176391)
**期刊：** Lancet (London, England)
**PMID：** 41176391
**DOI：** 10.1016/S0140-6736(25)01188-2

### 第一部分 原文与翻译

**英文原标题：** Partial progress in sexual and reproductive health and rights: the influence of sociocultural, behavioural, structural, and technological changes on epidemiological trends.

**英文摘要原文：**
The concept of sexual and reproductive health and rights has evolved in the 21st century from previous narrower conceptualisations. In 2018, the Guttmacher-Lancet Commission proposed a broader and integrated defining framework, together with a package of essential health service elements. Despite this, progress on the sexual and reproductive health agenda has been inconsistent, with progress in some areas and considerable gaps in others. Even in areas that have seen breakthroughs in biomedicine and technology, progress has been partial owing to inadequacies in funding, policy, and implementation. Additionally, initial executive orders of the Trump administration in early 2025 presented a major challenge to sexual and reproductive health and rights in the USA, and orders on US foreign aid threaten devastating impacts on sexual and reproductive health and rights in recipient low-income and middle-income countries. As discussions of sexual and reproductive health and rights are often seen to be sensitive or controversial, even when had at a senior government level, any consideration of time trends in sexual and reproductive health outcomes need to consider the complex interplay between trends in social and cultural factors, politics and legal frameworks, and technology and biomedicine. The perceived sensitivity of sexual and reproductive health means that providing adequate education on sex, sexuality, and relationships is crucial, and this education is often resisted by religion or traditionalist sentiments. Furthermore, technological change means that many young people receive this education online, which has both positive and negative effects. A thorough understanding of the driving factors behind global epidemiological trends in sexual and reproductive health-such as fluidity in gender and sexual identity, biomedical innovations in contraception and the treatment and prevention of HIV and other sexually transmitted infections, gender-based violence, access to safe abortion, fertility needs, and comprehensive sexuality education-is crucial in assessing progress on the sexual and reproductive health and rights agenda. To this end, this Series paper provides an overview of trends in sexual and reproductive health and rights outcomes since 2018.

**中文摘要译文：**
在21世纪，性与生殖健康及权利的概念已从先前较为狭隘的观念演变而来。2018年，古特马赫-柳叶刀委员会提出了一个更广泛、更综合的定义框架，以及一揽子基本卫生服务要素。尽管如此，性与生殖健康议程的进展一直不均衡，在某些领域取得了进步，但在其他领域则存在相当大的差距。即使在生物医学和技术取得突破的领域，由于资金、政策和实施方面的不足，进展也只是局部的。此外，特朗普政府在2025年初的初步行政命令对美国的性与生殖健康及权利构成了重大挑战，而关于美国对外援助的命令则可能对受援中低收入国家的性与生殖健康及权利造成毁灭性影响。由于关于性与生殖健康及权利的讨论，即使在政府高层进行，也常常被视为敏感或有争议，因此任何对性与生殖健康结果时间趋势的考量，都需要考虑到社会文化因素、政治法律框架、技术与生物医学趋势之间复杂的相互作用。性与生殖健康的敏感性意味着提供关于性、性行为和两性关系的充分教育至关重要，而这种教育常常受到宗教或传统主义情绪的抵制。此外，技术变革意味着许多年轻人通过网络接受这种教育，这既有积极影响，也有消极影响。为了评估性与生殖健康及权利议程的进展，透彻理解全球性与生殖健康流行病学趋势背后的驱动因素至关重要——例如性别与性身份的流动性、避孕及艾滋病毒和其他性传播感染治疗与预防的生物医学创新、基于性别的暴力、安全堕胎的可及性、生育需求以及全面的性教育。为此，本系列论文概述了自2018年以来性与生殖健康及权利结果的趋势。

### 第二部分 AI 大师评价

本文是一篇系统性综述，旨在概述自2018年以来全球性与生殖健康及权利（SRHR）领域的进展与挑战。文章深入剖析了社会文化、政治法律、生物医学及技术变革等多重因素如何共同影响SRHR的流行病学趋势，指出尽管在生物技术等方面有所突破，但由于资金、政策及执行不力，整体进展仍不均衡。其核心价值在于提供了一个宏观且多维度的分析框架，强调了理解性别认同流动性、在线性教育、安全堕胎可及性等复杂驱动因素的重要性。作为《柳叶刀》系列文章之一，该文对于指导未来全球公共卫生政策的制定、识别研究重点及推动SRHR议程具有重要的参考意义和深远影响。

---

## 8. 旨在减少胃癌的幽门螺杆菌人群筛查——作者的答复

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41176388](https://pubmed.ncbi.nlm.nih.gov/41176388)
**期刊：** Lancet (London, England)
**PMID：** 41176388
**DOI：** 10.1016/S0140-6736(25)01957-9

### 第一部分 原文与翻译

**英文原标题：** Population screening for Helicobacter pylori to reduce gastric cancer - Authors' reply.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文并非一篇原创性研究，而是作者针对其早前发表的关于“通过人群筛查幽门螺杆菌以预防胃癌”研究的相关评论或问题所作的答复。这类文献反映了学术界对于该重要公共卫生策略的持续关注和深入探讨。通过回应，作者可能进一步澄清了其研究的设计、结果解读或局限性，这对于推动该领域的共识形成和未来研究方向具有重要价值。由于缺乏摘要，无法获知其具体答复内容，但其标题本身就强调了幽门螺杆菌筛查在胃癌一级预防中的核心地位及围绕其展开的学术讨论。

---

## 9. 通过人群筛查幽门螺杆菌以减少胃癌

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41176387](https://pubmed.ncbi.nlm.nih.gov/41176387)
**期刊：** Lancet (London, England)
**PMID：** 41176387
**DOI：** 10.1016/S0140-6736(25)01736-2

### 第一部分 原文与翻译

**英文原标题：** Population screening for Helicobacter pylori to reduce gastric cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该标题揭示了一项具有重要公共卫生意义的研究，其核心目的在于探讨通过大规模人群筛查幽门螺杆菌（Hp）来降低胃癌发病率的可行性与效果。鉴于Hp感染是胃癌最主要的风险因素，本研究直接触及了胃癌一级预防的核心策略。若该筛查策略被证实有效，将为全球胃癌防控提供高级别证据，并可能改变临床实践指南。然而，由于摘要缺失，无法评估其具体研究设计、关键数据和结论，需详阅原文方能获得全面认识。

---

## 10. 转移性鳞状非小细胞肺癌患者治疗结局的进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41176378](https://pubmed.ncbi.nlm.nih.gov/41176378)
**期刊：** Lancet (London, England)
**PMID：** 41176378
**DOI：** 10.1016/S0140-6736(25)02172-5

### 第一部分 原文与翻译

**英文原标题：** Progress in outcomes for patients with metastatic squamous non-small-cell lung cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献标题明确指出，本文旨在综述转移性鳞状非小细胞肺癌患者在治疗结局方面取得的进展。由于缺乏摘要，无法得知具体的研究方法和关键发现，但推测其可能系统性地总结了近年来免疫治疗、靶向治疗等新疗法对改善该类患者生存率和生活质量的积极影响。此类综述对于临床医生掌握前沿动态、优化治疗决策具有重要的指导价值，并可能为未来的研究方向提供启示。

---

## 11. 高风险骨髓增生异常综合征（HR-MDS）药物开发的困境：从近期失败的III期临床试验中汲取的经验教训。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41175364](https://pubmed.ncbi.nlm.nih.gov/41175364)
**期刊：** Blood
**PMID：** 41175364
**DOI：** 10.1182/blood.2025029727

### 第一部分 原文与翻译

**英文原标题：** The conundrum of drug development in higher-risk MDS: Lessons learned from recently failed phase 3 clinical trials.

**英文摘要原文：**
Aside from allogeneic transplantation, the current standard of care approach for higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) remains monotherapy with a hypomethylating agent (HMA) including azacitidine, decitabine, or oral decitabine/cedazuridine. Many attempts using HMA-based combinations have failed to improve upon HMA monotherapy. While promising efficacy was observed in early phase clinical trials with several agents, subsequent randomized phase 3 trials failed to confirm improvements in complete response (CR) rates or overall survival. In this review, we discuss lessons learned from the recently reported negative trials of azacitidine in combination with eprenetapopt (APR-246), magrolimab, pevonedistat, sabatolimab, tamibarotene, and venetoclax. First, we make a case for emphasizing biological classification rather than disease risk status alone to select patients for HR-MDS trials. Second, we argue that TP53 inactivated MDS and CMML patients should be treated in dedicated clinical trials. Alternatively, if TP53 inactivated MDS is included in HR-MDS trials, then randomization stratification by TP53 inactivation status should be considered. Third, we caution against ignoring signals of excessive toxicity and premature investigational agent discontinuation observed in early phase trials. Fourth, we show that the International Working Group (IWG) 2006 response criteria, long used in HR-MDS trials, can both overestimate and underestimate the true therapeutic benefit. Instead, we advocate for using the IWG 2023 response criteria to better capture clinically meaningful benefits in HR-MDS. Lastly, we emphasize the need for the scientific community to access patient-level data and samples from failed phase 3 trials in an efficient and expedited fashion to inform the development of subsequent trials.

**中文摘要译文：**
除异基因移植外，当前针对高风险骨髓增生异常综合征/肿瘤（HR-MDS）的标准治疗方法仍是使用去甲基化药物（HMA）单药治疗，包括阿扎胞苷、地西他滨或口服地西他滨/西达尿苷。许多基于HMA的联合用药方案未能显示出优于HMA单药治疗的效果。尽管在一些药物的早期临床试验中观察到了有希望的疗效，但随后的随机III期试验证实，这些方案未能改善完全缓解（CR）率或总生存期。在这篇综述中，我们探讨了从近期报道的阿扎胞苷联合eprenetapopt（APR-246）、magrolimab、pevonedistat、sabatolimab、tamibarotene和venetoclax的失败试验中获得的教训。首先，我们主张在为HR-MDS试验筛选患者时，应强调生物学分类，而不仅仅是疾病风险状态。其次，我们认为TP53失活的MDS和CMML患者应在专门的临床试验中进行治疗。或者，如果将TP53失活的MDS纳入HR-MDS试验，则应考虑按TP53失活状态进行随机化分层。第三，我们告诫不应忽视在早期试验中观察到的过度毒性和研究性药物过早停用的信号。第四，我们指出，长期用于HR-MDS试验的国际工作组（IWG）2006年疗效评价标准，既可能高估也可能低估真实的治疗获益。为此，我们提倡使用IWG 2023年疗效评价标准，以更好地捕捉HR-MDS中具有临床意义的获益。最后，我们强调科学界需要以高效、快捷的方式获取失败的III期试验中的患者层面数据和样本，从而为后续试验的设计提供信息。

### 第二部分 AI 大师评价

这篇发表于《Blood》的综述深刻剖析了高风险骨髓增生异常综合征（HR-MDS）领域药物研发的严峻挑战，通过系统性地复盘近期多个III期临床试验失败案例，总结了宝贵的经验教训。文章的核心论点在于，未来的临床试验设计应超越传统的风险分层，更加注重患者的生物学特征（如TP53突变状态）、警惕早期毒性信号，并采纳更新的疗效评价标准（IWG 2023）。该文的价值不在于报告新的实验数据，而在于为该领域的未来研究提供了极具临床指导意义的战略性反思与前瞻性建议，对优化试验设计、避免重蹈覆辙至关重要。

---

## 12. 抗PD-1一线治疗经典型霍奇金淋巴瘤的可行性与安全性：我们是否看到了全貌？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41175363](https://pubmed.ncbi.nlm.nih.gov/41175363)
**期刊：** Blood
**PMID：** 41175363
**DOI：** 10.1182/blood.2025029935

### 第一部分 原文与翻译

**英文原标题：** Feasibility and Safety of Anti-PD1 First-Line Treatment of Classic Hodgkin Lymphoma: Do We See the Full Picture?

**英文摘要原文：**
Classic Hodgkin Lymphoma (cHL) is highly curable with risk-adapted first-line treatment. Due to exceptional efficacy, anti-programmed cell death protein 1 antibodies (aPD1) are increasingly incorporated into first-line treatment. The short- and long-term immune-related adverse event (irAE) burden in this setting, however, is insufficiently understood. Herein, we review the currently available evidence on feasibility and safety of aPD1 first-line cHL treatment. A more harmonized and complete reporting is critical to enable a detailed understanding and comprehensive assessment of aPD1-related morbidity.

**中文摘要译文：**
经典型霍奇金淋巴瘤（cHL）通过风险分层的一线治疗有很高的治愈率。由于其卓越的疗效，抗程序性死亡蛋白1（anti-programmed cell death protein 1, aPD1）抗体正越来越多地被纳入一线治疗方案。然而，在这种治疗背景下，短期和长期的免疫相关不良事件（irAE）负担尚未得到充分了解。在此，我们回顾了关于aPD1一线治疗cHL的可行性与安全性的现有证据。更统一和完整的报告对于深入理解和全面评估aPD1相关的发病情况至关重要。

### 第二部分 AI 大师评价

该文献是一篇关于抗PD-1单抗一线治疗经典型霍奇金淋巴瘤（cHL）的综述。文章的核心目的在于审视将aPD1疗法前移至一线应用的现有证据，并重点关注其安全性和可行性。作者通过回顾现有研究指出，尽管aPD1疗效显著，但其短期及长期的免疫相关不良事件（irAE）负担尚未被充分阐明。本综述的价值在于敏锐地指出了当前研究中的一个关键知识缺口，并强调了建立统一、完整不良事件报告标准的重要性，这对于未来临床实践的风险评估和试验设计具有重要的指导意义。

---

## 13. 围手术期卡瑞利珠单抗联合利沃西拉尼对比单纯手术治疗可切除肝细胞癌

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41125108](https://pubmed.ncbi.nlm.nih.gov/41125108)
**期刊：** Lancet (London, England)
**PMID：** 41125108
**DOI：** 10.1016/S0140-6736(25)02104-X

### 第一部分 原文与翻译

**英文原标题：** Perioperative camrelizumab plus rivoceranib versus surgery in resectable hepatocellular carcinoma.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该研究旨在评估围手术期应用卡瑞利珠单抗（一种PD-1抑制剂）联合利沃西拉尼（一种抗血管生成药物）对比单纯手术治疗可切除肝细胞癌的疗效。此项研究的核心创新在于将新辅助/辅助免疫联合靶向治疗引入可切除肝癌的治疗模式，意图改善高复发风险患者的预后。尽管缺乏摘要信息，但从标题推断，该研究若能证实联合治疗在生存获益或病理缓解率上的优势，则可能为早期肝癌的围手术期综合治疗提供重要循证医学证据，并有望改变临床实践。

---

## 14. 探索为一线转移性结直肠癌制定基于风险调整的CT检查方案

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40998093](https://pubmed.ncbi.nlm.nih.gov/40998093)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40998093
**DOI：** 10.1016/j.annonc.2025.09.010

### 第一部分 原文与翻译

**英文原标题：** Toward risk-adjusted CT schedules in first-line metastatic colorectal cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该研究标题表明，其核心目的在于探索如何为接受一线治疗的转移性结直肠癌患者制定个体化的、基于风险分层的计算机断层扫描（CT）随访计划。尽管暂无摘要信息，但此标题揭示了研究试图摆脱“一刀切”的传统监测模式，转向更为精准的个体化管理策略。这项研究的潜在价值巨大，若能成功建立风险模型，将有助于优化医疗资源分配，减少低风险患者的过度检查，同时加强对高风险患者的监测以更早发现疾病进展。然而，由于缺乏具体摘要，我们无法评估其所采用的研究方法、数据支持和结论的可靠性。

---

## 15. 蒽环类药物在基因组高风险、淋巴结阴性、HR阳性/HER2阴性乳腺癌中的作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40972946](https://pubmed.ncbi.nlm.nih.gov/40972946)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40972946
**DOI：** 10.1016/j.annonc.2025.08.002

### 第一部分 原文与翻译

**英文原标题：** Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer.

**英文摘要原文：**
BACKGROUND: The benefit of anthracyclines for patients with high 21-gene recurrence score (RS) is unclear, despite the widespread use of RS to guide adjuvant chemotherapy treatment for hormone receptor (HR)-positive /human epidermal growth factor receptor 2 (HER2)-negative breast cancer. This study aimed to assess whether patients with RS ≥ 31 would have improved outcomes with the addition of anthracyclines to taxane-based chemotherapy.

PATIENTS AND METHODS: We included patients from TAILORx with RS ≥ 11 who received treatment with either taxanes with cyclophosphamide (TC) or taxane with anthracyclines/cyclophosphamide (T-AC). Distant recurrence-free interval (DRFI), distant recurrence-free survival (DRFS), and overall survival (OS) were compared, controlling for age, tumor size and grade, receptor status, and RS. Spline regression was used to estimate adjusted hazard ratio (aHR) for receipt of T-AC (versus TC) for these endpoints as a function of RS.

RESULTS: A total of 2549 patients who received either T-AC or TC were included in the primary analysis. In patients with RS ≥ 31, receipt of T-AC was associated with improved DRFI (5-year rate of 96.1% with T-AC versus 91.0% with TC, aHR 0.31, P = 0.006), DRFS (95.4% versus 89.8%, aHR 0.49, P = 0.032), and a trend toward improved OS (adjusted 5-year rate 97.3% versus 93.6%, aHR 0.67, P = 0.31). Spline regression demonstrated increasing anthracycline benefit with increasing RS.

CONCLUSION: Patients with early-stage, HR-positive/HER2-negative breast cancer with the highest genomic risk disease (RS ≥ 31) may benefit from the addition of an anthracycline to taxane-based adjuvant chemotherapy. Genomic RS testing may predict anthracycline benefit more accurately than clinicopathological factors such as nodal status.

**中文摘要译文：**
背景：尽管21基因复发评分（RS）被广泛用于指导激素受体（HR）阳性/人表皮生长因子受体2（HER2）阴性乳腺癌的辅助化疗，但对于高RS患者，蒽环类药物的获益尚不明确。本研究旨在评估在以紫杉烷为基础的化疗方案中加入蒽环类药物，是否能改善RS≥31患者的预后。

患者与方法：我们纳入了来自TAILORx研究中RS≥11的患者，这些患者接受了紫杉烷联合环磷酰胺（TC）或紫杉烷联合蒽环类/环磷酰胺（T-AC）的治疗。在控制了年龄、肿瘤大小和分级、受体状态及RS后，比较了两组的无远处复发间期（DRFI）、无远处复发生存（DRFS）和总生存期（OS）。采用样条回归分析，评估接受T-AC方案（相对于TC方案）在这些终点事件上，作为RS函数的校正风险比（aHR）。

结果：共有2549名接受T-AC或TC方案治疗的患者被纳入主要分析。在RS≥31的患者中，接受T-AC方案与改善的DRFI（5年率：T-AC组96.1% vs TC组91.0%，aHR 0.31, P = 0.006）、改善的DRFS（95.4% vs 89.8%，aHR 0.49, P = 0.032）以及OS改善趋势（校正后5年率：97.3% vs 93.6%，aHR 0.67, P = 0.31）相关。样条回归分析表明，蒽环类药物的获益随RS的升高而增加。

结论：对于具有最高基因组风险（RS≥31）的早期HR阳性/HER2阴性乳腺癌患者，在以紫杉烷为基础的辅助化疗中加入蒽环类药物可能会使其获益。基因组RS检测可能比淋巴结状态等临床病理因素更准确地预测蒽环类药物的获益。

### 第二部分 AI 大师评价

本研究精准聚焦于一个临床难题：对于基因组高风险（RS≥31）的HR+/HER2-、淋巴结阴性乳腺癌患者，是否需要使用蒽环类药物。研究基于著名的TAILORx试验数据进行分析，发现对于RS≥31的患者，含蒽环方案（T-AC）相比TC方案显著改善了远期复发相关生存终点。这项发现极具临床价值，它提示对于基因检测认定的“最高危”人群，强化治疗仍然是必要的，并强调了基因复发评分在预测化疗获益方面可能优于传统的淋巴结状态等临床指标。

---

## 16. 塑造前列腺癌Lu-PSMA-617放射性配体疗法的未来：早期治疗更优，还是精准筛选患者是关键？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40945704](https://pubmed.ncbi.nlm.nih.gov/40945704)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40945704
**DOI：** 10.1016/j.annonc.2025.09.002

### 第一部分 原文与翻译

**英文原标题：** Shaping the future of Lu-PSMA-617 radiopharmaceutical therapy in prostate cancer: is earlier better, or is patient selection key?

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献标题点明了前列腺癌治疗领域的一项关键策略性讨论。文章聚焦于Lu-PSMA-617放射性配体疗法，探讨了其未来发展的两大核心方向：是应该将治疗时机前移，还是应该优化患者选择标准。此文可能是一篇述评或观点性文章，通过权衡这两种策略的优劣，旨在为该疗法在临床实践中的最佳应用提供指导，并为未来的研究设计提供重要参考。这对于最大化治疗获益和推动前列腺癌精准医疗的发展具有重要意义。

---

## 17. 自身免疫病风险基因ANKRD55通过代谢调节促进TH17的效应功能

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40932625](https://pubmed.ncbi.nlm.nih.gov/40932625)
**期刊：** The Journal of experimental medicine
**PMID：** 40932625
**DOI：** 10.1084/jem.20250185

### 第一部分 原文与翻译

**英文原标题：** Autoimmune disease risk gene ANKRD55 promotes TH17 effector function through metabolic modulation.

**英文摘要原文：**
Genome-wide association studies (GWAS) have linked the locus encoding ankyrin repeat domain 55 (ANKRD55) with numerous autoimmune diseases; however, its biological function and role in inflammation are unclear. Here, we demonstrate that Ankrd55-deficient mice are protected from T cell-mediated colitis but are more susceptible to Citrobacter rodentium infection. Mechanistically, Ankrd55 deletion impairs CD4+ T cell proliferation and reduces effector cytokine production in T helper 17 (TH17) cells in a cell-intrinsic manner. ANKRD55 is associated with mitochondria, and its loss is associated with impaired mitochondrial respiration and activation of the LKB1 pathway. Consistently, IL-17 production can be rescued by the deletion of LKB1 in Ankrd55-deficient T cells. Altogether, our study implicates the protein ANKRD55 as a functional modulator of T cell metabolism that directly impacts TH17 responses, highlighting it as a potential target across multiple autoimmune diseases.

**中文摘要译文：**
全基因组关联研究（GWAS）已将编码锚蛋白重复域55（ANKRD55）的基因位点与多种自身免疫病关联起来；然而，其生物学功能及在炎症中的作用尚不清楚。本研究中，我们证明了Ankrd55缺陷小鼠能抵抗T细胞介导的结肠炎，但对柠檬酸杆菌感染更为易感。从机制上讲，Ankrd55的缺失以细胞内在的方式损害了CD4+ T细胞的增殖，并减少了辅助性T细胞17（TH17）中效应细胞因子的产生。ANKRD55与线粒体相关，其缺失与线粒体呼吸受损及LKB1通路的激活有关。一致地是，在Ankrd55缺陷的T细胞中，删除LKB1可以恢复IL-17的产生。总而言之，我们的研究表明ANKRD55蛋白是T细胞代谢的功能调节剂，直接影响TH17的应答，这凸显了其作为多种自身免疫病潜在治疗靶点的价值。

### 第二部分 AI 大师评价

本研究旨在阐明与多种自身免疫病相关的风险基因ANKRD55的具体生物学功能。研究通过构建Ankrd55基因缺陷小鼠模型，发现该基因对于维持TH17细胞的效应功能至关重要。其创新之处在于，首次揭示了ANKRD55通过调控线粒体呼吸与LKB1信号通路，进而影响T细胞的代谢和功能，为理解自身免疫病的发病机制提供了新的分子视角，并指出了ANKRD55可能成为一个广谱的自身免疫病治疗靶点。

---

## 18. 转移性乳腺癌全身治疗的更新建议：源自ESMO动态临床实践指南

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40930896](https://pubmed.ncbi.nlm.nih.gov/40930896)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40930896
**DOI：** 10.1016/j.annonc.2025.07.017

### 第一部分 原文与翻译

**英文原标题：** Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是欧洲肿瘤内科学会（ESMO）发布的转移性乳腺癌动态指南的更新版本，旨在为临床医生提供最新的全身治疗建议。作为一份重要的临床实践指南，其核心价值在于系统性地整合了最新的临床试验证据，并由领域内专家委员会达成共识，从而指导治疗决策。该指南采用“动态（Living）”形式，体现了其快速响应和纳入新研究成果的先进性，确保了临床实践的前沿性。虽然摘要缺失，但可以预见，该指南的更新将对全球转移性乳腺癌的临床实践产生直接而深远的影响。

---

## 19. 早期和局部晚期非小细胞肺癌：ESMO临床实践指南（诊断、治疗与随访）

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40885528](https://pubmed.ncbi.nlm.nih.gov/40885528)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40885528
**DOI：** 10.1016/j.annonc.2025.08.003

### 第一部分 原文与翻译

**英文原标题：** Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是欧洲肿瘤内科学会（ESMO）发布的关于早期及局部晚期非小细胞肺癌（NSCLC）的临床实践指南。作为权威的指导性文件，它旨在为临床医生提供从诊断、治疗到长期随访的全程管理标准和循证建议。该指南的发布对于规范全球范围内NSCLC的临床实践、优化治疗策略、改善患者预后具有至关重要的指导价值。尽管摘要缺失，但ESMO指南通常基于对最新临床研究证据的系统性回顾和专家共识，代表了该领域的最高学术水平和实践标准。

---

## 20. 按PSA最低值分层的转移性激素敏感性前列腺癌患者十年生存率：ECOG-ACRIN 3805 (CHAARTED) 试验的长期生存分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40854410](https://pubmed.ncbi.nlm.nih.gov/40854410)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40854410
**DOI：** 10.1016/j.annonc.2025.08.004

### 第一部分 原文与翻译

**英文原标题：** Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.

**英文摘要原文：**
BACKGROUND: The CHAARTED trial investigated the long-term survival of patients with metastatic hormone-sensitive prostate cancer (HSPC) treated with androgen deprivation therapy (ADT) with or without docetaxel (Taxotere). This analysis focuses on 10-year overall survival (OS) stratified by disease volume and on-therapy prostate-specific antigen (PSA) levels at 6 months.

PATIENTS AND METHODS: OS was calculated using the Kaplan-Meier method from randomization to death or last known alive date. Patients were grouped based on baseline disease characteristics [high-volume (HV) or low-volume (LV)] and PSA levels at 6 months (<0.2 ng/ml versus ≥0.2 ng/ml). Multivariable Cox regression analysis was used to evaluate correlation of PSA nadir with OS adjusted for treatment arm, disease volume, Gleason score, and prior local therapy.

RESULTS: Of 790 patients, 225 were without recorded death after a median follow-up of 10 years. The 10-year OS was 25.9% (ADT + docetaxel) versus 22.5% [ADT; hazard ratio (HR) 0.78, P = 0.004]. HV patients treated with docetaxel had significantly higher OS (20.9% versus 11.4%, P < 0.0001). PSA <0.2 ng/ml at 6 months was associated with improved median OS in both ADT + docetaxel (100.3 versus 45.4 months, P < 0.0001) and ADT (116.8 versus 31.8 months, P < 0.0001) arms. PSA nadir <0.2 ng/l at 6 months was an independent predictor of improved OS (HR 0.41, P < 0.0001) adjusting for disease volume, prior local therapy, Gleason score and treatment arm.

CONCLUSIONS: Long-term follow-up confirms that ADT + docetaxel significantly improves OS in metastatic HSPC patients with HV disease. PSA nadir <0.2 ng/ml at 6 months is a strong prognostic marker for OS, supporting its use in response-adapted de-escalation strategies.

**中文摘要译文：**
背景：CHAARTED试验研究了接受雄激素剥夺疗法（ADT）联合或不联合多西他赛（泰索帝）治疗的转移性激素敏感性前列腺癌（HSPC）患者的长期生存情况。本分析重点关注根据疾病负荷和治疗6个月时的前列腺特异性抗原（PSA）水平分层的十年总生存率（OS）。

患者与方法：总生存期（OS）采用Kaplan-Meier法计算，自随机化开始至死亡或最后已知存活日期为止。根据基线疾病特征[高负荷（HV）或低负荷（LV）]和6个月时的PSA水平（<0.2 ng/ml vs ≥0.2 ng/ml）对患者进行分组。采用多变量Cox回归分析评估PSA最低值与OS的相关性，并对治疗组、疾病负荷、Gleason评分和既往局部治疗等因素进行了校正。

结果：在790名患者中，经过中位10年的随访，有225名患者无死亡记录。十年总生存率（OS）在ADT联合多西他赛组为25.9%，而在ADT单独治疗组为22.5%[风险比（HR）0.78，P = 0.004]。接受多西他赛治疗的高负荷（HV）患者的总生存率显著更高（20.9% vs 11.4%，P < 0.0001）。在ADT联合多西他赛治疗组（100.3个月 vs 45.4个月，P < 0.0001）和ADT单独治疗组（116.8个月 vs 31.8个月，P < 0.0001）中，治疗6个月时PSA水平<0.2 ng/ml均与中位总生存期的改善相关。在校正了疾病负荷、既往局部治疗、Gleason评分和治疗方案后，6个月时PSA最低值<0.2 ng/ml是OS改善的独立预测因子（HR 0.41，P < 0.0001）。

结论：长期随访证实，ADT联合多西他赛可显著改善高负荷（HV）疾病的转移性HSPC患者的总生存期。治疗6个月时PSA最低值<0.2 ng/ml是OS的强有力预后标志物，支持其在反应适应性降阶梯治疗策略中的应用。

### 第二部分 AI 大师评价

本研究基于经典的CHAARTED试验进行了长达十年的随访分析，旨在评估多西他赛联合ADT治疗转移性激素敏感性前列腺癌（mHSPC）的长期疗效，并探索早期PSA反应的预后价值。研究通过对生存数据的分层和多变量分析，关键性地证实了对于高负荷患者，联合化疗能带来显著的长期生存获益。其核心创新价值在于，明确了治疗6个月时PSA水平降至<0.2 ng/ml是一个强效且独立的预后预测因子，这一发现为未来制定基于疗效反应的个体化治疗策略（如治疗降阶梯）提供了高级别循证医学证据。

---

## 21. 一线转移性结直肠癌治疗中疾病进展风险以指导疾病再评估：AIO与GONO对11项试验的汇总分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40840710](https://pubmed.ncbi.nlm.nih.gov/40840710)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40840710
**DOI：** 10.1016/j.annonc.2025.08.001

### 第一部分 原文与翻译

**英文原标题：** Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessments-analysis of 11 trials by AIO and GONO.

**英文摘要原文：**
BACKGROUND: We evaluated the distribution and risk of disease progression (PD) in first-line therapy of unresected metastatic colorectal cancer (mCRC) patients receiving chemotherapy + biologics. The aim of the analysis is to provide guidance for the timing of disease reassessments during first-line therapy.

PATIENTS AND METHODS: Individual data of 2939 unresected patients from TRIBE, MOMA, TRIBE2, VALENTINO, ATEZOTRIBE, TRIPLETE, FIRE-3, XELAVIRI, PANAMA, FIRE-4 and FIRE-4.5 were analyzed. The frequency and risk of PD events were calculated for individual timepoints during therapy. RAS/BRAF profiling, tumor sidedness, type of therapy and early tumor shrinkage (ETS) were used to identify subgroups for risk assessment. A Cox regression model to predict first-line progression-free survival (PFS) was built.

RESULTS: In the overall population, the maximum frequency of PD events was observed at 7.6 months, with an absolute PD risk of 19%. Then, the PD risk flattened, achieving a maximum of 23% at 14 months in RAS/BRAF-wild-type patients (n = 1786), 25% at 10 months in RAS-mutant patients (n = 973) and 35% at 8 months in BRAF-mutant patients (n = 180). Eastern Cooperative Oncology Group performance status >0, right-sidedness, initially unresected primary tumor, higher number of organs involved by metastases and BRAF mutation were independently associated with a higher risk of PD in first line. The impact of baseline characteristics on PFS was mitigated after incorporation of ETS in the model.

CONCLUSIONS: The distribution of PD events does not follow a Gaussian pattern, with the highest density observed between the third and fourth reassessment of a bimonthly surveillance schedule. In clearly unresectable patients, restaging should focus on the interval between 6 and 10 months and not on the initiation of systemic therapy. Our model might be helpful to schedule radiological reassessments according to baseline characteristics, early response and the expected duration of each treatment efficacy.

**中文摘要译文：**
背景：我们评估了接受化疗联合生物制剂一线治疗的未切除转移性结直肠癌（mCRC）患者的疾病进展（PD）分布与风险。本分析旨在为一线治疗期间疾病再评估的时机提供指导。

患者与方法：本研究分析了来自TRIBE、MOMA、TRIBE2、VALENTINO、ATEZOTRIBE、TRIPLETE、FIRE-3、XELAVIRI、PANAMA、FIRE-4和FIRE-4.5共11项试验的2939例未切除mCRC患者的个体数据。我们计算了治疗期间各个时间点的PD事件频率与风险。通过RAS/BRAF分型、肿瘤原发部位、治疗类型和早期肿瘤缩小（ETS）来识别不同亚组以进行风险评估。此外，还建立了一个Cox回归模型以预测一线无进展生存期（PFS）。

结果：在总人群中，PD事件的最高频率出现在7.6个月时，绝对PD风险为19%。随后，PD风险曲线趋于平缓，在RAS/BRAF野生型患者（n = 1786）中于14个月时达到23%的峰值，在RAS突变型患者（n = 973）中于10个月时达到25%的峰值，在BRAF突变型患者（n = 180）中于8个月时达到35%的峰值。美国东部肿瘤协作组（ECOG）体力状况评分>0、右半结肠、原发灶初始未切除、转移器官数量较多以及BRAF突变是与一线治疗中更高PD风险独立相关的因素。在模型中纳入ETS后，基线特征对PFS的影响有所减弱。

结论：PD事件的分布不遵循高斯模式，其最高密度出现在双月监测方案的第三次和第四次再评估之间。对于明确不可切除的患者，影像学再分期的重点应放在6至10个月的区间，而非系统治疗开始时。我们的模型可能有助于根据基线特征、早期缓解情况以及每种治疗方案的预期疗效持续时间来安排影像学再评估。

### 第二部分 AI 大师评价

本研究通过对11项大型临床试验的近3000名患者数据进行汇总分析，旨在精准刻画一线治疗中转移性结直肠癌的疾病进展风险模式。其核心创新在于揭示了疾病进展并非均匀发生，而是在特定时间点（6-10个月）达到高峰，且该高峰因RAS/BRAF基因状态而异。该研究不仅为临床制定个体化的影像学监测策略提供了强有力的数据支持，避免了不必要的早期或过于频繁的评估，还构建了一个整合了早期肿瘤反应的预测模型，对优化治疗决策和资源分配具有重要的临床指导价值。

---

## 22. 早发性结直肠癌的发病趋势与长期生存：一项瑞典全国性研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40816336](https://pubmed.ncbi.nlm.nih.gov/40816336)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40816336
**DOI：** 10.1016/j.annonc.2025.07.019

### 第一部分 原文与翻译

**英文原标题：** Incidence trends and long-term survival in early-onset colorectal cancer: a nationwide Swedish study.

**英文摘要原文：**
BACKGROUND: Early-onset colorectal cancer (EOCRC, diagnosis before age 50) is increasing globally. Survival comparisons with late-onset colorectal cancer (CRC) are inconsistent, however, and long-term excess mortality remains poorly understood. This Swedish population-based study aimed to evaluate trends in incidence, survival, and long-term excess mortality in early- versus late-onset CRC.

MATERIALS AND METHODS: We identified all incident colorectal adenocarcinomas recorded in the Swedish National Cancer Register from 1993 to 2019. Incidence trends were quantified using annual percentage changes and relative survival differences were assessed using excess mortality rate ratios, both from Poisson regression models with 95% confidence intervals (CIs).

RESULTS: A total of 47 864 right-sided colon, 40 664 left-sided colon, and 47 082 rectal cancer cases were included. EOCRC patients were more frequently diagnosed with metastatic disease, compared with late-onset CRC. EOCRC incidence increased across all subsites, with annual percentage changes ranging from 2.04 (95% CI 1.51-2.56) for rectal to 2.64 (95% CI 2.02-2.37) for right-sided colon cancer, while an increase among late-onset cases was observed only for right-sided colon cancer. Crude 5-year relative survival was similar across age groups, but after full adjustment (including metastatic stage), EOCRC was associated with better survival, with excess mortality rate ratios ranging from 0.76 (95% CI 0.68-0.84) for rectal cancer to 0.83 (95% CI 0.74-0.92) for right-sided colon cancer. Notably, excess mortality remained elevated 5-10 years after diagnosis in both age groups.

CONCLUSIONS: EOCRC incidence is increasing in Sweden, aligning with global trends. Although younger patients were more often diagnosed at an advanced stage of disease, they had similar crude survival and better stage-adjusted survival, compared with older patients. The persistent long-term excess mortality in both groups, even during periods when CRC patients are typically considered statistically cured, highlights the need for extended follow-up and tailored survivorship care.

**中文摘要译文：**
背景：早发性结直肠癌（EOCRC，50岁前诊断）在全球范围内呈上升趋势。然而，与晚发性结直肠癌（CRC）的生存率比较尚无定论，且其长期超额死亡率仍不明确。本项基于瑞典人群的研究旨在评估早发性与晚发性CRC在发病率、生存率及长期超额死亡率方面的趋势。

材料与方法：我们从1993年至2019年的瑞典国家癌症登记中心确定了所有结直肠腺癌新发病例。我们使用年度百分比变化来量化发病趋势，并采用超额死亡率比值来评估相对生存差异，两者均通过泊松回归模型（含95%置信区间，CI）进行计算。

结果：研究共纳入47,864例右半结肠癌、40,664例左半结肠癌及47,082例直肠癌病例。与晚发性CRC患者相比，EOCRC患者确诊时更常为转移性疾病。EOCRC在所有亚部位的发病率均呈上升趋势，其年度百分比变化范围从直肠癌的2.04（95% CI 1.51-2.56）到右半结肠癌的2.64（95% CI 2.02-2.37）不等；而在晚发性病例中，仅观察到右半结肠癌发病率有所增加。各年龄组的粗略5年相对生存率相似，但在进行充分校正（包括转移分期）后，EOCRC与更优的生存率相关，其超额死亡率比值范围从直肠癌的0.76（95% CI 0.68-0.84）到右半结肠癌的0.83（95% CI 0.74-0.92）。值得注意的是，在诊断后的5-10年间，两个年龄组的超额死亡率均持续偏高。

结论：瑞典的EOCRC发病率持续上升，与全球趋势一致。尽管年轻患者确诊时常处于疾病晚期，但与年长患者相比，其粗略生存率相似，而经分期校正后的生存率更优。两个年龄组中持续存在的长期超额死亡率（即便是在CRC患者通常被认为已达到统计学治愈的时期）凸显了延长随访和提供个体化生存期照护的必要性。

### 第二部分 AI 大师评价

本研究基于瑞典全国性大数据，系统分析了早发性结直肠癌（EOCRC）的发病与生存趋势。其核心发现揭示了一个重要悖论：尽管年轻患者确诊时分期更晚，但经分期校正后的生存率反而优于年长患者。该研究最具价值的贡献在于，清晰指出了两个年龄组在诊断后5-10年仍存在持续的超额死亡风险，这对传统的“统计学治愈”观念提出了挑战。这一发现对于优化癌症筛查策略、制定更长期的随访计划和个体化生存期照护具有重要的临床指导意义。

---

## 23. 淋巴瘤：ESMO诊断、治疗及随访临床实践指南

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40774601](https://pubmed.ncbi.nlm.nih.gov/40774601)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40774601
**DOI：** 10.1016/j.annonc.2025.07.014

### 第一部分 原文与翻译

**英文原标题：** Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是欧洲肿瘤内科学会（ESMO）发布的关于淋巴瘤诊断、治疗和随访的临床实践指南。这类指南通常由领域内权威专家团队系统性回顾最新研究证据后制定，旨在为临床医生提供标准化的、基于证据的决策支持。作为重要且权威的指导性文件，本指南对规范全球范围内淋巴瘤的临床实践、优化患者管理策略以及指导未来研究方向具有至关重要的价值和深远影响。

---

## 24. HER2阳性早期乳腺癌降阶梯新辅助治疗后生存的预测：三项WSG试验的汇总分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40769278](https://pubmed.ncbi.nlm.nih.gov/40769278)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40769278
**DOI：** 10.1016/j.annonc.2025.07.016

### 第一部分 原文与翻译

**英文原标题：** Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials.

**英文摘要原文：**
BACKGROUND: We analyzed outcomes and survival predictors in three West German Study Group (WSG) randomized de-escalation trials (ADAPT-HR-/HER2+, ADAPT-TP, TP-II) in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC) investigating short (12-week) neoadjuvant treatments with or without chemotherapy.

PATIENTS AND METHODS: A total of 713 patients were analyzed; neoadjuvant chemotherapy (paclitaxel plus pertuzumab plus trastuzumab): n = 149, neoadjuvant chemotherapy-free (pertuzumab plus trastuzumab, trastuzumab-only)/antibody-drug conjugate (ADC, trastuzumab emtansine) treatment: n = 564. Patients with pathological complete response (pCR, ypT0/is ypN0) were allowed to omit further chemotherapy; chemotherapy was mandatory after non-pCR. The primary endpoint of each trial was pCR; survival was the secondary endpoint. Survival was analyzed using the Kaplan-Meier method and Cox regression.

RESULTS: Median follow-up was 60.7 months. In total, 10 (7%) and 74 (13%) invasive disease-free survival (iDFS) events, 8 (5%) and 51 (9%) distant DFS (dDFS) events, and 6 (4%) and 34 (6%) deaths occurred in the neoadjuvant chemotherapy and chemotherapy-free/ADC groups, respectively; the respective 5-year survival rates were 96% [95% confidence interval (CI) 92% to 99%] and 88% (95% CI 85% to 91%) for iDFS (hazard ratio 0.56, 95% CI 0.29-1.08, P = 0.083) and 98% (95% CI 93% to 99%) and 97% (95% CI 95% to 98%) for overall survival (hazard ratio 0.88, 95% CI 0.36-2.11, P = 0.775). The 5-year iDFS rates in patients with pCR were 98% (95% CI 91% to 99%) after chemotherapy and 94% (95% CI 89% to 97%) after chemotherapy-free/ADC treatment (hazard ratio 0.76, 95% CI 0.27-2.12, P = 0.609). iDFS was comparable between patients with and without adjuvant chemotherapy after pCR to chemotherapy-free/ADC treatment (hazard ratio 1.25, 95% CI 0.39-4.00, P = 0.712). In multivariable analysis, node-negative status and pCR were favorably associated with iDFS in the chemotherapy-free/ADC group.

CONCLUSIONS: This pooled analysis demonstrates that neoadjuvant de-escalation trials with further pCR-adapted treatment (de-)escalation are feasible and appear safe for HER2-positive eBC patients. Twelve-weekly neoadjuvant paclitaxel plus HER2 blockade is effective and well tolerated. Neoadjuvant chemotherapy-free/ADC treatments can be viable alternatives for stage I-II eBC. Excellent survival after pCR to neoadjuvant chemotherapy-free/ADC treatment lays the groundwork for further de-escalation strategies.

**中文摘要译文：**
背景：我们分析了三项西德研究组（WSG）随机降阶梯试验（ADAPT-HR-/HER2+、ADAPT-TP、TP-II）的结局和生存预测因素，这些试验旨在研究人类表皮生长因子受体2（HER2）阳性早期乳腺癌（eBC）中，采用或不采用化疗的短期（12周）新辅助治疗方案。

患者与方法：共分析了713例患者；新辅助化疗组（紫杉醇联合帕妥珠单抗和曲妥珠单抗）：n=149，新辅助无化疗/抗体药物偶联物（ADC，恩美曲妥珠单抗）治疗组（帕妥珠单抗联合曲妥珠单抗，或仅用曲妥珠单抗）：n=564。获得病理学完全缓解（pCR, ypT0/is ypN0）的患者可以省略后续化疗；未达到pCR的患者则必须接受化疗。各试验的主要终点是pCR；生存为次要终点。采用Kaplan-Meier法和Cox回归分析生存数据。

结果：中位随访时间为60.7个月。在新辅助化疗组和无化疗/ADC组中，分别发生了10例（7%）和74例（13%）无浸润性疾病生存（iDFS）事件，8例（5%）和51例（9%）无远处转移生存（dDFS）事件，以及6例（4%）和34例（6%）死亡事件；两组的5年iDFS率分别为96%（95%置信区间[CI] 92%至99%）和88%（95% CI 85%至91%）（风险比0.56，95% CI 0.29-1.08, P=0.083），5年总生存率分别为98%（95% CI 93%至99%）和97%（95% CI 95%至98%）（风险比0.88，95% CI 0.36-2.11, P=0.775）。化疗后达到pCR的患者5年iDFS率为98%（95% CI 91%至99%），而无化疗/ADC治疗后达到pCR的患者为94%（95% CI 89%至97%）（风险比0.76，95% CI 0.27-2.12, P=0.609）。在无化疗/ADC治疗后达到pCR的患者中，接受或不接受辅助化疗的患者其iDFS相当（风险比1.25，95% CI 0.39-4.00, P=0.712）。在多变量分析中，淋巴结阴性状态和pCR与无化疗/ADC组的iDFS呈有利相关。

结论：该汇总分析表明，对于HER2阳性eBC患者，采用新辅助降阶梯治疗并根据pCR情况对后续治疗进行（降）阶梯调整的策略是可行且安全的。为期12周的新辅助紫杉醇联合HER2靶向治疗方案有效且耐受性良好。对于I-II期eBC，新辅助无化疗/ADC治疗方案是可行的替代选择。在新辅助无化疗/ADC治疗后获得pCR的患者展现出极佳的生存率，这为进一步的治疗降阶梯策略奠定了基础。

### 第二部分 AI 大师评价

本研究通过对三项WSG临床试验的汇总分析，旨在评估HER2阳性早期乳腺癌患者接受降阶梯新辅助治疗（包含或不含化疗）后的生存结局及预测因素。研究关键发现，基于病理学完全缓解（pCR）指导的（降）阶梯治疗策略是安全可行的，尤其是对于接受无化疗/ADC新辅助方案并获得pCR的患者，其预后极佳。该研究的价值在于为特定患者群体（如I-II期、淋巴结阴性）安全地省略化疗、减轻治疗负担提供了高质量证据，为HER2阳性乳腺癌的精准化、个体化降阶梯治疗开辟了新路径。

---

## 25. 1级间质性肺病/肺炎恢复后重新接受曲妥珠单抗-德鲁司替康治疗的汇总分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40769277](https://pubmed.ncbi.nlm.nih.gov/40769277)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40769277
**DOI：** 10.1016/j.annonc.2025.07.015

### 第一部分 原文与翻译

**英文原标题：** Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis.

**英文摘要原文：**
BACKGROUND: Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate treatment for multiple solid tumors, carries risk of interstitial lung disease/pneumonitis (ILD). Management guidelines generally mandate interrupting T-DXd treatment for grade 1 ILD, with possible retreatment following resolution of imaging findings. This pooled analysis examined T-DXd retreatment duration and ILD recurrence following recovery from grade 1 ILD.

PATIENTS AND METHODS: Data were pooled from nine clinical trials of patients with various human epidermal growth factor receptor 2 (HER2)-positive, HER2-low, or HER2 (ERBB2)-mutant solid tumors treated with T-DXd (5.4-8.0 mg/kg). ILD events were reported and graded by investigators and confirmed as drug related by an independent ILD adjudication committee. Patients who recovered from a first investigator-assessed grade 1 and adjudication committee-confirmed drug-related ILD event (ILD1) could receive T-DXd retreatment. Patients were evaluated until disease progression or data cut-off.

RESULTS: Among 2145 pooled patients, 9% (193/2145) had grade 1 ILD1, of which 23.3% (45/193) were retreated with T-DXd. Median retreatment duration was 85 days (range 1-848 days); 17.8% (8/45) of patients received T-DXd retreatment for ≥1 year. ILD recurrence (ILD2) occurred in 33.3% (15/45) of retreated patients; median time to ILD2 from T-DXd retreatment was 64 days (range, 22-391 days) and were low-grade events (grade 1, n = 6; grade 2, n = 9; no grade ≥3 or fatal events). Reasons for T-DXd retreatment discontinuation were disease progression [33.3% (15/45)]; ILD recurrence [20% (9/45)]; non-ILD adverse events [17.8% (8/45)]; and physician's decision [4.4% (2/45)]. At the analysis cut-off, 24.4% (11/45) of retreated patients were still receiving treatment, and most patients with ILD2 [60% (9/15)] had recovered with/without sequelae.

CONCLUSIONS: This first large-scale pooled analysis demonstrates the safety of T-DXd retreatment after recovery from grade 1 ILD. ILD recurred in one-third of patients; all recurrence events were grade 1/2 and manageable using existing treatment guidelines. T-DXd retreatment following resolution of grade 1 drug-related ILD has potential to maximize therapeutic benefit.

**中文摘要译文：**
背景：曲妥珠单抗-德鲁司替康（T-DXd）是一种用于治疗多种实体瘤的抗体-药物偶联物，但存在引发间质性肺病/肺炎（ILD）的风险。治疗指南通常要求，对于1级ILD患者需中断T-DXd治疗，待影像学检查结果恢复正常后可考虑重新治疗。本项汇总分析旨在研究从1级ILD中恢复后，重新接受T-DXd治疗的持续时间以及ILD的复发情况。

患者与方法：本研究汇总了九项临床试验的数据，这些试验的受试者为接受T-DXd（5.4-8.0 mg/kg）治疗的、患有各类型人表皮生长因子受体2（HER2）阳性、HER2低表达或HER2（ERBB2）突变实体瘤的患者。ILD事件由研究者报告并分级，并由一个独立的ILD裁定委员会确认为药物相关。首次经研究者评估为1级且经裁定委员会确认为药物相关的ILD事件（ILD1）中恢复的患者，可重新接受T-DXd治疗。对患者的评估持续至疾病进展或数据截止日期。

结果：在汇总的2145名患者中，9%（193/2145）的患者发生了1级ILD1，其中23.3%（45/193）的患者重新接受了T-DXd治疗。中位再治疗持续时间为85天（范围1-848天）；17.8%（8/45）的患者接受T-DXd再治疗的时间≥1年。在重新接受治疗的患者中，33.3%（15/45）发生了ILD复发（ILD2）；从T-DXd再治疗到ILD2发生的中位时间为64天（范围22-391天），且均为低级别事件（1级，n=6；2级，n=9；无≥3级或致死性事件）。T-DXd再治疗中断的原因包括疾病进展[33.3% (15/45)]、ILD复发[20% (9/45)]、非ILD不良事件[17.8% (8/45)]以及医生决定[4.4% (2/45)]。在分析截止时，24.4%（11/45）的再治疗患者仍在接受治疗，且大多数发生ILD2的患者[60% (9/15)]已经恢复（伴有或不伴有后遗症）。

结论：这项首次进行的大规模汇总分析证实了在1级ILD恢复后重新进行T-DXd治疗的安全性。约三分之一的患者出现ILD复发；所有复发事件均为1/2级，并可通过现有治疗指南进行管理。在1级药物相关性ILD消退后重新进行T-DXd治疗，具有最大化治疗获益的潜力。

### 第二部分 AI 大师评价

本研究通过对九项临床试验的汇总分析，首次大规模评估了因1级间质性肺病（ILD）中断治疗后，恢复并重新接受曲妥珠单抗-德鲁司替康（T-DXd）治疗的安全性。研究发现，尽管约三分之一的患者会复发ILD，但所有复发事件均为低级别且可控，证实了再治疗的可行性。这项研究为临床实践提供了重要循证依据，支持在严密监测下对发生轻度ILD的患者继续使用T-DXd，从而最大化患者的潜在治疗获益。

---

## 26. 各类新兴KRAS抑制剂的基因组耐药机制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40744807](https://pubmed.ncbi.nlm.nih.gov/40744807)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40744807
**DOI：** 10.1016/j.annonc.2025.06.019

### 第一部分 原文与翻译

**英文原标题：** Mechanisms of genomic resistance across emerging classes of KRAS inhibitors.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

根据该文献标题判断，这可能是一篇综述或基础研究，旨在系统性阐述各类新型KRAS抑制剂在临床应用中出现的基因组层面上的耐药机制。KRAS作为曾经“不可成药”的靶点，其抑制剂的出现是肿瘤靶向治疗的里程碑，但耐药性是限制其长期疗效的关键瓶颈。该研究聚焦于基因组学的耐药机制，对于指导后续KRAS抑制剂的优化、开发克服耐药的新药以及制定联合用药策略具有重要的科学价值和临床指导意义。由于暂无摘要，无法获知其具体的研究方法和关键发现。

---

## 27. 关于NATALEE研究最终无浸润性疾病生存分析：对Mimura等人及Hu和Yang的读者来信的回复

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40744806](https://pubmed.ncbi.nlm.nih.gov/40744806)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40744806
**DOI：** 10.1016/j.annonc.2025.06.013

### 第一部分 原文与翻译

**英文原标题：** Reply to Letters to the Editor by Mimura et al. and Hu and Yang regarding the NATALEE final invasive disease-free survival analysis.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

本文并非一项原创性研究，而是一篇针对NATALEE研究最终无浸润性疾病生存分析的“读者来信回复”。其核心目的在于回应Mimura等人及Hu和Yang对该研究提出的疑问或评论，作者可能就研究设计、数据解读或结论的稳健性进行了进一步的澄清与论证。此类学术通信对于促进同行间的科学对话、确保重要临床试验结果的准确理解和应用至关重要，是已发表研究后续学术讨论和严谨性验证的重要组成部分。

---

## 28. 原发灶不明癌与TNM分期：患者管理的新范式

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40701441](https://pubmed.ncbi.nlm.nih.gov/40701441)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40701441
**DOI：** 10.1016/j.annonc.2025.07.007

### 第一部分 原文与翻译

**英文原标题：** Cancer of unknown primary site and TNM staging: a new paradigm for patient management.

**英文摘要原文：**
Cancer of unknown primary site (CUP) is a syndrome of many different metastatic cancers arising from clinically occult primary tumors. There has been no established staging system applicable since it has not been possible to identify an anatomical primary tumor. In recent years, the globally accepted American Joint Committee on Cancer TNM (tumor-node-metastasis) staging manuals briefly addressed a few rare CUP subsets with highly suspected primary tumors (breast, oropharynx, nasopharynx, melanoma) that could be designated as primary category T0 (no evidence of primary tumor). Similar logic may now be applied to many other patients and TNM staging is an evolving narrative. Diagnostic pathology, particularly immunohistochemical staining and molecular testing, interpreted in the context of clinical features are now capable of diagnosing presumptive occult primaries with reasonable certainty in many other patients creating an avenue for a T0 category as a specific cancer type. This new diagnostic paradigm of lifting the veil of the unknown for some patients and separating them from the historical nondescript CUP diagnosis allows for TNM staging, precision site-specific therapy (SST), prognostication, evaluating treatment results and continuing investigation. Once the tumor type is unmasked and staged, additional molecular characterization and SST are indicated. Many CUP subsets now meet these criteria and considerable clinical trial data have revealed that their outcomes from SST appear superior to empiric chemotherapy and similar to their counterparts with overt primary tumors, although additional prospective comparative studies are warranted. Eventually most of the cancers responsible for the enigmatic CUP syndrome will be identified, making CUP an irrelevant clinical entity.

**中文摘要译文：**
原发灶不明癌（CUP）是一种由临床上隐匿的原发肿瘤引起的多种不同转移性癌症构成的综合征。由于无法确定解剖学上的原发肿瘤，因此一直没有适用的既定分期系统。近年来，全球公认的美国癌症联合委员会（AJCC）的TNM（肿瘤-淋巴结-转移）分期手册简要论述了少数高度怀疑原发肿瘤（乳腺癌、口咽癌、鼻咽癌、黑色素瘤）的罕见CUP亚型，这些亚型可被归为原发肿瘤分类T0（无原发肿瘤证据）。现在，类似的逻辑可能也适用于许多其他患者，TNM分期是一个不断演进的概念。诊断病理学，特别是免疫组织化学染色和分子检测，结合临床特征进行解读，现在能够在许多其他患者中以合理的确定性诊断出推定的隐匿性原发灶，从而为将T0类别作为一个特定癌症类型开辟了途径。这种为部分患者揭开未知面纱、并将其与历史上笼统的CUP诊断区分开来的新诊断范式，使得TNM分期、精准的部位特异性治疗（SST）、预后判断、治疗结果评估和持续研究成为可能。一旦肿瘤类型被揭示并完成分期，就需要进行额外的分子特征分析和SST。现在许多CUP亚型都符合这些标准，大量的临床试验数据表明，这些患者接受SST的结局似乎优于经验性化疗，且与那些有明确原发肿瘤的同类患者相似，尽管仍需进行更多前瞻性比较研究。最终，导致神秘的CUP综合征的大多数癌症将被识别出来，使CUP成为一个不再具有临床意义的实体。

### 第二部分 AI 大师评价

本文提出了一种针对原发灶不明癌（CUP）患者管理的革命性新范式。文章论述了通过先进的病理诊断技术（如免疫组化和分子检测）确定推定的原发肿瘤，并将其纳入TNM分期系统（归为T0），从而摒弃了传统的笼统性诊断。这一创新性转变使得对CUP患者进行精准的部位特异性治疗和预后评估成为可能，显著提升了治疗效果。该文为CUP的临床实践和未来研究指明了新方向，预示着随着诊断技术的进步，CUP这一概念或将最终成为历史。

---

## 29. 浸润性小叶乳腺癌患者的临床挑战与解决方案建议

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40701440](https://pubmed.ncbi.nlm.nih.gov/40701440)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40701440
**DOI：** 10.1016/j.annonc.2025.07.008

### 第一部分 原文与翻译

**英文原标题：** Clinical challenges and proposed solutions for patients with invasive lobular breast cancer.

**英文摘要原文：**
BACKGROUND: Invasive lobular carcinoma (ILC) is the second most common type of breast cancer and is increasingly recognized as a separate entity from invasive breast cancer of no-special type. Here, we present the current standings and challenges of clinical ILC research and discuss possible solutions to address these challenges.

DESIGN: European and United States experts on ILC have summarized the recent developments, ongoing endeavors and remaining challenges concerning the histopathological diagnosis, imaging and treatment of ILC.

RESULTS: Recent endeavors have led to guidelines for a more uniform and standardized pathological diagnosis of ILC. Future efforts are needed to refine the histological and biological subclassification and determine the indications for use of artificial intelligence for pathological diagnosis. Since standard-of-care imaging tools are suboptimal for ILC screening and local and systemic staging, new modalities such as contrast-enhanced mammography, novel positron emission tomography tracers and diffusion-weighted magnetic resonance imaging are under investigation. An alternative to the currently used RECIST v1.1 criteria is needed for clinical trial response assessment, as it is not uniformly applicable for patients with metastatic ILC. The use of liquid biopsies for detecting disease progression needs dedicated research. Regarding treatment, the efficacy of novel breast cancer therapies needs to be examined specifically for ILC, and evaluation of drugs targeting ILC-specific or enriched targets is warranted.

CONCLUSIONS: While great progress has been made in ILC research, many challenges remain and require further investigation in the clinic to optimize treatment and outcomes for those diagnosed with this common tumor type.

**中文摘要译文：**
背景：浸润性小叶癌（ILC）是第二大最常见的乳腺癌类型，并日益被认为是独立于非特殊类型浸润性乳腺癌的一种独特实体。在此，我们介绍了当前ILC临床研究的现状与挑战，并探讨了应对这些挑战的可能解决方案。

设计：来自欧洲和美国的ILC专家总结了关于ILC组织病理学诊断、影像学及治疗方面的最新进展、正在进行中的努力以及尚存的挑战。

结果：近期的努力已促成了更统一和标准化的ILC病理诊断指南的制定。未来需要进一步努力以完善组织学和生物学亚分型，并确定人工智能在病理诊断中的应用指征。由于标准治疗的影像学工具在ILC筛查、局部及全身分期方面效果不佳，新的技术模式如对比增强乳腺X线摄影、新型正电子发射断层扫描示踪剂和扩散加权磁共振成像等正在研究中。由于现行的RECIST v1.1标准并不普遍适用于转移性ILC患者，因此需要一种替代方案用于临床试验的疗效评估。利用液体活检检测疾病进展需要专门的研究。在治疗方面，需要专门检验新型乳腺癌疗法对ILC的疗效，并且有必要评价针对ILC特异性或富集靶点的药物。

结论：尽管ILC研究已取得巨大进展，但仍有许多挑战尚存，需要进一步的临床研究，以优化这种常见肿瘤类型患者的治疗和结局。

### 第二部分 AI 大师评价

该文献是一篇由欧美专家撰写的综述性文章，旨在全面总结浸润性小叶癌（ILC）在组织病理学诊断、影像学评估及临床治疗方面所面临的核心挑战。文章明确指出，现有诊断标准、影像技术和疗效评价体系（如RECIST v1.1）对ILC的适用性有限，限制了患者的精准诊疗。作者们进一步提出了未来的研究方向，包括完善病理亚分型、开发新型影像技术、探索液体活检应用以及研发针对ILC特异性靶点的药物。作为一篇高水平的专家述评，本文对统一学术界认识、指导未来临床试验设计和推动ILC个体化治疗策略的发展具有重要的指导价值。

---

## 30. OpeRa试验：患者在临床决策过程和手术规划中的主动作用。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40692099](https://pubmed.ncbi.nlm.nih.gov/40692099)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40692099
**DOI：** 10.1016/j.annonc.2025.07.006

### 第一部分 原文与翻译

**英文原标题：** The OpeRa trial: the active role of the patient in the clinical decision-making process and surgical planning.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究（OpeRa试验）旨在探讨患者在临床决策与手术规划中发挥主动作用的影响。该研究聚焦于以患者为中心的医疗模式，通过一项临床试验来评估共享决策在外科治疗领域的重要性。尽管目前尚无摘要可供深入分析其具体方法和研究结果，但该研究课题本身具有重要的临床意义，有望为改善医患沟通、优化治疗方案提供新的证据。

---

## 31. 新诊断高风险局限性或转移性激素敏感性前列腺癌患者的骨折相关住院：一项利用医疗系统数据对STAMPEDE III期试验中多西他赛和唑来膦酸进行的二次分析。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40680994](https://pubmed.ncbi.nlm.nih.gov/40680994)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40680994
**DOI：** 10.1016/j.annonc.2025.07.005

### 第一部分 原文与翻译

**英文原标题：** Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data.

**英文摘要原文：**
BACKGROUND: Androgen deprivation therapy (ADT), the mainstay systemic treatment for high risk non-metastatic (M0) and metastatic (M1) prostate cancer is associated with bone loss and increased fracture risk. The STAMPEDE trial tested the addition of zoledronic acid (ZA) ± docetaxel (with prednisolone) to ADT. Both regimens may impact bone health. However, long-term fracture incidence remains uncertain.

PATIENTS AND METHODS: Health systems data were obtained for patients recruited from England and randomised to standard-of-care (SOC) ADT compared with SOC plus ZA or docetaxel or both docetaxel and ZA. ICD10 diagnosis and OPCS procedure codes from inpatient hospital admissions were used to identify fracture-related hospitalisations. Flexible parametric competing risks models were used to estimate 5- and 10-year cumulative incidence and sub-distribution hazard ratios (SDHR).

RESULTS: 2140 of 2705 (79%) patients recruited from trial sites in England were eligible for this secondary analysis. Linked data were available for 2042/2140 (96%) pts (734 M0, 1308 M1). 5-year cumulative incidence of fracture for M0 and M1 patients treated with SOC only was 11% [95% confidence interval (CI), 8% to 15%] and 23% (95% CI, 19% to 28%), respectively. 10-year cumulative incidence in M0 patients was 26% (95% CI, 20% to 33%). Allocation to ZA significantly reduced the risk of fracture in M1 patients (SDHR 0.73, 95% CI 0.55-0.97; P = 0.015) but not M0 patients (SDHR 0.88, 95% CI 0.59-1.32; P = 0.549). Docetaxel had no clear effect on the risk of fracture in M0 (P = 0.570) or M1 (P = 0.264) patients.

CONCLUSIONS: High cumulative incidence of fracture was observed in both M0 and M1 prostate cancer patients receiving ADT. The addition of ZA to ADT ± docetaxel significantly reduced long-term fracture risk in M1 participants but had no clear effect in M0 disease. These data support the use of bone protective agents to reduce fracture risk in men with M1 prostate cancer undergoing ADT.

**中文摘要译文：**
背景：雄激素剥夺疗法（ADT）是高风险非转移性（M0）和转移性（M1）前列腺癌的主要系统性治疗方法，但其与骨量减少和骨折风险增加相关。STAMPEDE试验测试了在ADT基础上加用唑来膦酸（ZA）±多西他赛（联合泼尼松龙）的方案。这两种方案都可能影响骨骼健康。然而，其长期骨折发生率尚不明确。

患者与方法：本研究获取了从英格兰招募的患者的医疗系统数据，这些患者被随机分配至标准治疗（SOC）组（接受ADT）或在SOC基础上加用ZA、多西他赛或ZA联合多西他赛的治疗组。研究使用住院患者的ICD10诊断编码和OPCS操作编码来识别骨折相关的住院事件。采用灵活的参数化竞争风险模型来估计5年和10年累积发生率及亚分布风险比（SDHR）。

结果：从英格兰各试验中心招募的2705名患者中，有2140名（79%）符合本次二次分析的资格。其中，2042名（96%）患者（734名M0，1308名M1）获得了可用的关联数据。仅接受SOC治疗的M0和M1患者，其5年累积骨折发生率分别为11% [95%置信区间（CI），8%至15%]和23% [95% CI，19%至28%]。M0患者的10年累积发生率为26% [95% CI，20%至33%]。分配至ZA组显著降低了M1患者的骨折风险（SDHR 0.73, 95% CI 0.55-0.97; P = 0.015），但在M0患者中未见此效果（SDHR 0.88, 95% CI 0.59-1.32; P = 0.549）。多西他赛对M0（P = 0.570）或M1（P = 0.264）患者的骨折风险没有明确影响。

结论：在接受ADT的M0和M1前列腺癌患者中，均观察到较高的累积骨折发生率。在ADT±多西他赛的基础上加用ZA可显著降低M1患者的长期骨折风险，但对M0患者无明确效果。这些数据支持对接受ADT的M1前列腺癌男性患者使用骨保护剂以降低骨折风险。

### 第二部分 AI 大师评价

本研究基于STAMPEDE III期临床试验，创新性地利用英国医疗系统的大数据，对接受雄激素剥夺疗法（ADT）的高风险或转移性前列腺癌患者的长期骨折风险进行了二次分析。其核心发现明确指出，转移性（M1）前列腺癌患者在ADT基础上联用唑来膦酸可显著降低骨折风险，而对于非转移性（M0）患者则无此显著效果。这项研究为转移性前列腺癌患者常规使用骨保护剂以预防骨相关事件提供了强有力的真实世界证据，对临床实践具有重要的指导价值。

---

## 32. 针对未经紫杉烷类药物治疗的转移性去势抵抗性前列腺癌患者，比较[177Lu]Lu-PSMA-617与更换雄激素受体通路抑制剂的III期PSMAfore试验的最终总生存期和安全性分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40680993](https://pubmed.ncbi.nlm.nih.gov/40680993)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40680993
**DOI：** 10.1016/j.annonc.2025.07.003

### 第一部分 原文与翻译

**英文原标题：** Final overall survival and safety analyses of the phase III PSMAfore trial of [Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.

**英文摘要原文：**
BACKGROUND: In PSMAfore, [Lu]Lu-PSMA-617 (Lu-PSMA-617) prolonged radiographic progression-free survival (rPFS) in taxane-naive patients with metastatic castration-resistant prostate cancer (mCRPC), with a favourable safety profile, versus a change in androgen receptor pathway inhibitor (ARPI). We report the final overall survival (OS) analysis and updated safety data.

PATIENTS AND METHODS: PSMAfore (NCT04689828) was an open-label, international, phase III trial. Patients with prostate-specific membrane antigen (PSMA)-positive mCRPC who had experienced disease progression once on a previous ARPI and were candidates for ARPI change were randomized 1 : 1 to Lu-PSMA-617 or ARPI change to abiraterone or enzalutamide. Crossover from ARPI change to Lu-PSMA-617 was allowed after centrally confirmed radiographic progression. Endpoints included rPFS (primary), OS (key secondary), and safety (secondary).

RESULTS: Patients were randomized to Lu-PSMA-617 or ARPI change (n = 234 each): 141/234 participants (60.3%) randomized to ARPI change crossed over (75.4% of those with centrally confirmed radiographic progression). The median OS was 24.48 months [95% confidence interval (CI) 19.55-28.94 months] with Lu-PSMA-617 versus 23.13 months (95% CI 19.61-25.53 months) with ARPI change [hazard ratio (HR) 0.91, 95% CI 0.72-1.14, P = 0.20] based on the intention-to-treat (ITT) principle; the crossover-adjusted OS HR by inverse probability of censoring weighting modelling was 0.59 (95% CI 0.38-0.91). For Lu-PSMA-617 versus ARPI change, exposure-adjusted incidences of grade ≥3 and serious treatment-emergent adverse events were 60.8 versus 85.1 and 32.5 versus 49.9 per 100 patient-treatment years, respectively. Dry mouth occurred in 135/227 participants (59.5%; 2/227 grade ≥3) and anaemia in 62/227 (27.3%; 14/227 grade ≥3) in the Lu-PSMA-617 arm.

CONCLUSIONS: OS analyses did not show a statistically significant difference between the Lu-PSMA-617 and ARPI arms based on the ITT principle; results were likely confounded by the high rate of crossover. The safety profile of Lu-PSMA-617 was favourable with no new safety signals identified.

**中文摘要译文：**
背景：在PSMAfore试验中，对于未经紫杉烷类药物治疗的转移性去势抵抗性前列腺癌（mCRPC）患者，与更换雄激素受体通路抑制剂（ARPI）相比，[177Lu]Lu-PSMA-617（Lu-PSMA-617）延长了影像学无进展生存期（rPFS），并具有良好的安全性。本报告旨在公布最终的总生存期（OS）分析和更新的安全性数据。

患者与方法：PSMAfore（NCT04689828）是一项开放标签、国际性的III期临床试验。研究纳入前列腺特异性膜抗原（PSMA）阳性、既往接受一种ARPI治疗后出现疾病进展且适合更换ARPI的mCRPC患者，将其1:1随机分配至Lu-PSMA-617组或更换ARPI（阿比特龙或恩扎卢胺）组。对于ARPI更换组，在经中心确认出现影像学进展后，允许交叉至Lu-PSMA-617治疗。研究终点包括rPFS（主要终点）、OS（关键次要终点）和安全性（次要终点）。

结果：患者被随机分配至Lu-PSMA-617组或ARPI更换组（每组n = 234）：ARPI更换组中141/234名参与者（60.3%）发生了交叉（占经中心确认影像学进展者的75.4%）。基于意向性治疗（ITT）原则，Lu-PSMA-617组的中位OS为24.48个月[95%置信区间（CI）19.55-28.94个月]，而ARPI更换组为23.13个月（95% CI 19.61-25.53个月）[风险比（HR）0.91, 95% CI 0.72-1.14, P = 0.20]；通过逆概率审查加权模型进行交叉校正后的OS HR为0.59（95% CI 0.38-0.91）。在Lu-PSMA-617组与ARPI更换组中，经暴露时间校正后，每100个患者治疗年的≥3级治疗期间不良事件和严重不良事件的发生率分别为60.8 vs 85.1和32.5 vs 49.9。在Lu-PSMA-617组中，135/227名参与者（59.5%；其中2/227为≥3级）出现口干，62/227名（27.3%；其中14/227为≥3级）出现贫血。

结论：基于ITT原则的OS分析未显示Lu-PSMA-617组与ARPI组之间存在统计学显著差异；这一结果可能受到了高交叉率的干扰。Lu-PSMA-617的安全性良好，未发现新的安全性信号。

### 第二部分 AI 大师评价

该研究报告了关键的III期PSMAfore试验的最终总生存期（OS）结果，旨在评估[177Lu]Lu-PSMA-617在化疗前线mCRPC患者中的疗效与安全性。其核心发现是，尽管因对照组向治疗组存在高比例交叉（60.3%），意向性治疗（ITT）分析未显示出OS的统计学差异，但经交叉校正后的分析揭示了显著的生存获益。这项研究的临床价值巨大，它有力地支持了将此创新的放射性配体疗法用于更前线的治疗，并证实了其良好的安全性，预示着可能改变mCRPC的治疗标准。

---

## 33. 头颈癌术后放化疗的再探讨：RTOG 9501/EORTC 22931研究的更新长期联合分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40680992](https://pubmed.ncbi.nlm.nih.gov/40680992)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40680992
**DOI：** 10.1016/j.annonc.2025.07.004

### 第一部分 原文与翻译

**英文原标题：** Re-examining post-operative chemoradiotherapy in head and neck cancer: an updated long-term combined analysis of RTOG 9501/EORTC 22931.

**英文摘要原文：**
BACKGROUND: Post-operative chemoradiation (CRT) is generally recommended for head and neck cancer patients with extranodal extension (ENE) and/or positive margins, but not for patients without these features, based on a post hoc analysis of Radiation Therapy Oncology Group (RTOG) 9501 and European Organisation for Research and Treatment of Cancer (EORTC) 22931. However, this analysis lacked tests of interaction necessary to identify a predictive biomarker. In addition, updated data are now available.

PATIENTS AND METHODS: This study assessed 744 patients enrolled on RTOG 9501 and EORTC 22931, randomized trials that compared CRT with radiation (RT) following surgery. Overall survival (OS) was analyzed with Cox regression. Cancer-specific mortality (CSM), other-cause mortality (OCM), and recurrence outcomes were analyzed with competing risks methodology. Tests of interaction assessed for differential benefits of CRT in various subgroups.

RESULTS: Median follow-up was 6.9 years. Among all patients, CRT improved OS [hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.68-0.97, P = 0.026]. Although CRT improved OS in the subgroup with ENE and/or positive margins (HR 0.71, 95% CI 0.57-0.89, P = 0.003) and not in those without these features (HR 0.94, 95% CI 0.68-1.30, P = 0.7), tests of interaction showed no evidence of a differential effect of CRT in these subgroups (P-interaction = 0.17). There was also no evidence of interaction when analyzing other outcomes, or when assessing ENE and margin status individually. While CRT significantly reduced CSM (HR 0.68, 95% CI 0.55-0.83, P < 0.001), it also significantly increased OCM (HR 1.51, 95% CI 1.07-2.12, P = 0.018). Post-operative CRT improved locoregional recurrence (HR 0.64, 95% CI 0.48-0.85, P = 0.002), but not distant metastasis (HR 0.83, 95% CI 0.64-1.08, P = 0.17).

CONCLUSIONS: Concurrent chemotherapy improved OS in head and neck cancer patients undergoing post-operative radiotherapy in the combined populations of EORTC 22931 and RTOG 9501. ENE and/or positive margins are not predictive biomarkers, and patients without these features may still benefit from CRT. CRT improved CSM, but this was partly offset by higher OCM. Refining the population most likely to benefit from post-operative CRT, taking into consideration both oncologic and patient-related factors, needs further exploration.

**中文摘要译文：**
背景：根据放射治疗肿瘤学组（RTOG）9501研究和欧洲癌症研究与治疗组织（EORTC）22931研究的一项事后分析，术后放化疗（CRT）通常被推荐用于有淋巴结外侵（ENE）和/或切缘阳性的头颈癌患者，但对于无这些特征的患者则不推荐。然而，该分析缺乏必要的交互作用检验来确定一个预测性生物标志物。此外，现在已获得了更新的数据。

患者与方法：本研究评估了入组RTOG 9501和EORTC 22931研究的744名患者，这两项随机试验旨在比较术后放化疗与单纯放疗（RT）的疗效。总生存期（OS）采用Cox回归进行分析。癌症特异性死亡率（CSM）、其他原因死亡率（OCM）以及复发结局采用竞争风险模型进行分析。交互作用检验用于评估CRT在不同亚组中的差异化获益。

结果：中位随访时间为6.9年。在所有患者中，CRT改善了OS [风险比（HR）0.81，95%置信区间（CI）0.68-0.97，P = 0.026]。尽管CRT在有ENE和/或切缘阳性的亚组中改善了OS（HR 0.71，95% CI 0.57-0.89，P = 0.003），而在无这些特征的患者中则未显示改善（HR 0.94，95% CI 0.68-1.30，P = 0.7），但交互作用检验显示，CRT在这些亚组中的效应并无差异性证据（P-交互作用=0.17）。在分析其他结局时，或在单独评估ENE和切缘状态时，也未发现交互作用的证据。虽然CRT显著降低了CSM（HR 0.68，95% CI 0.55-0.83，P < 0.001），但它也显著增加了OCM（HR 1.51，95% CI 1.07-2.12，P = 0.018）。术后CRT改善了局部区域复发（HR 0.64，95% CI 0.48-0.85，P = 0.002），但对远处转移无显著影响（HR 0.83，95% CI 0.64-1.08，P = 0.17）。

结论：在EORTC 22931和RTOG 9501研究的合并人群中，同步化疗改善了接受术后放疗的头颈癌患者的OS。ENE和/或切缘阳性并非预测性生物标志物，没有这些特征的患者仍可能从CRT中获益。CRT改善了CSM，但这部分获益被较高的OCM所抵消。未来需要进一步探索，结合肿瘤学因素和患者相关因素，以精准筛选出最可能从术后CRT中获益的人群。

### 第二部分 AI 大师评价

本研究基于两大经典临床试验（RTOG 9501/EORTC 22931）的更新长期数据，重新审视了头颈癌术后放化疗的获益人群。通过严谨的交互作用检验，研究颠覆性地指出，传统的“高危特征”（淋巴结外侵/切缘阳性）并非筛选获益人群的可靠预测指标，无此特征的患者同样可能从同步化疗中获益。此项发现对现行临床实践指南提出了挑战，强调了在降低癌症特异性死亡率的同时，也需关注化疗带来的非癌症死亡风险增加。该研究的价值在于推动临床医生超越传统风险分层，更精细化地权衡术后辅助治疗的利弊。

---

## 34. 泛-RAS或KRAS抑制剂治疗后胰腺癌获得性耐药的比较基因组图谱分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40623477](https://pubmed.ncbi.nlm.nih.gov/40623477)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40623477
**DOI：** 10.1016/j.annonc.2025.06.018

### 第一部分 原文与翻译

**英文原标题：** Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRAS inhibitors.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究旨在描绘并比较接受泛-RAS抑制剂或KRAS特异性抑制剂治疗后，胰腺癌出现获得性耐药的基因组图谱差异。通过对治疗前后肿瘤样本的基因组分析，该研究可能揭示了不同抑制剂策略下驱动耐药产生的关键基因突变或通路变化。这项工作对于理解胰腺癌的耐药机制、指导后续治疗策略（如联合用药或二线治疗选择）具有重要的临床指导意义和科研价值，为克服靶向治疗耐药这一核心挑战提供了新的见解。

---

## 35. 晚期ER阳性/HER2阴性乳腺癌患者治疗早期循环肿瘤DNA演变的预后意义

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40623476](https://pubmed.ncbi.nlm.nih.gov/40623476)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40623476
**DOI：** 10.1016/j.annonc.2025.06.015

### 第一部分 原文与翻译

**英文原标题：** Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer.

**英文摘要原文：**
BACKGROUND: Patients with advanced estrogen receptor-positive, HER2-negative breast cancer commonly develop resistance to treatment with hormone therapy and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Responders cannot be distinguished from nonresponders after the first cycle of treatment under current practice. We assessed circulating tumor DNA (ctDNA) measures at early timepoints as prognostic markers.

PATIENTS AND METHODS: Paired plasma samples were collected at baseline and early on-treatment (median 28 days) from 369 patients with advanced ER-positive/HER2-negative breast cancer treated in the PADA-1 trial with hormone therapy and a CDK4/6 inhibitor. Cell-free DNA was profiled with a 497-gene panel (Guardant360 LDT).

RESULTS: Baseline ctDNA levels, including the mean variant allele frequency (VAF) [progression-free survival (PFS) hazard ratio (HR) 1.07, 95% confidence interval (CI) 1.05-1.09), P < 0.001; overall survival (OS) HR 1.08, 95% CI 1.05-1.11, P < 0.001] and the number of driver somatic mutations (PFS HR 1.13, 95% CI 1.07-1.19, P < 0.001; OS HR 1.16, 95% CI 1.07-1.24, P < 0.001) were prognostic. Early on-treatment ctDNA dynamics were also associated with outcomes, including the number of driver somatic mutations with VAF > 0.5% at both timepoints (PFS HR 1.39, 95% CI 1.27-1.53, P < 0.001; OS HR 1.51, 95% CI 1.35-1.68, P < 0.001) and the number of driver somatic mutations with a VAF increase (PFS HR 1.31, 95% CI 1.19-1.44, P < 0.001; OS HR 1.10, 95% CI 1.02-1.18, P = 0.02). A ctDNA-based risk model incorporating baseline and dynamic ctDNA features was independently prognostic from RECIST in multivariable models (test set: OS HR 4.10, 95% CI 1.93-8.72, P < 0.001; PFS HR 1.86, 95% CI 1.16-2.97, P = 0.009). The integration of ctDNA features into a clinical model improved survival discrimination for PFS [C-index 64.7% (± 2.5%) for a ctDNA and clinical model versus 59.3% (± 2.2%) for a clinical-only model, P = 0.027] and for OS [C-index 70.0% (± 3.4%) versus 60.3% (± 4.2%), P = 0.035].

CONCLUSIONS: Early on-treatment evolution of ctDNA is prognostic for both PFS and OS in advanced ER-positive/HER2-negative breast cancer. A ctDNA-based risk model improves upon traditional RECIST and clinical parameters, advocating for ctDNA as a prognostic biomarker in clinical practice.

**中文摘要译文：**
背景: 晚期雌激素受体（ER）阳性、HER2阴性乳腺癌患者通常会对激素治疗联合细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂产生耐药。在当前临床实践中，无法在第一个治疗周期后区分出应答者与非应答者。我们评估了在治疗早期时间点的循环肿瘤DNA（ctDNA）检测作为预后标志物的价值。

患者与方法: 本研究从PADA-1试验中入组的369名接受激素治疗联合CDK4/6抑制剂的晚期ER阳性/HER2阴性乳腺癌患者中，收集了其基线及治疗早期（中位时间28天）的配对血浆样本。我们使用包含497个基因的panel（Guardant360 LDT）对无细胞DNA（cfDNA）进行了分析。

结果: 基线ctDNA水平，包括平均变异等位基因频率（VAF）[无进展生存期（PFS）风险比（HR）1.07，95%置信区间（CI）1.05-1.09，P < 0.001；总生存期（OS）HR 1.08，95% CI 1.05-1.11，P < 0.001]和驱动基因体细胞突变数量（PFS HR 1.13，95% CI 1.07-1.19，P < 0.001；OS HR 1.16，95% CI 1.07-1.24，P < 0.001）均具有预后价值。治疗早期的ctDNA动态变化同样与结局相关，包括在两个时间点VAF均>0.5%的驱动基因体细胞突变数量（PFS HR 1.39，95% CI 1.27-1.53，P < 0.001；OS HR 1.51，95% CI 1.35-1.68，P < 0.001）以及VAF升高的驱动基因体细胞突变数量（PFS HR 1.31，95% CI 1.19-1.44，P < 0.001；OS HR 1.10，95% CI 1.02-1.18，P = 0.02）。一个整合了基线和动态ctDNA特征的风险模型，在多变量分析中是独立于RECIST标准的预后因素（测试集：OS HR 4.10，95% CI 1.93-8.72，P < 0.001；PFS HR 1.86，95% CI 1.16-2.97，P = 0.009）。将ctDNA特征整合到临床模型中，提高了对PFS [C-index：ctDNA与临床模型为64.7% (± 2.5%)，纯临床模型为59.3% (± 2.2%)，P = 0.027]和OS [C-index：70.0% (± 3.4%) vs 60.3% (± 4.2%)，P = 0.035]的生存区分能力。

结论: 对于晚期ER阳性/HER2阴性乳腺癌，治疗早期的ctDNA演变对PFS和OS均有预后价值。一个基于ctDNA的风险模型优于传统的RECIST标准和临床参数，这支持将ctDNA作为一种预后生物标志物应用于临床实践。

### 第二部分 AI 大师评价

本研究旨在评估治疗早期循环肿瘤DNA（ctDNA）的动态变化对接受激素联合CDK4/6抑制剂治疗的晚期ER+/HER2-乳腺癌患者的预后价值。研究基于PADA-1试验的大样本数据，通过分析基线及治疗后28天的ctDNA特征，发现ctDNA的基线水平和早期动态变化均是无进展生存期和总生存期的强效预测因子。其创新之处在于构建了一个整合ctDNA动态特征的风险模型，该模型在预测能力上显著优于传统影像学评估（RECIST）和临床指标。这项发现有力推动了液体活检技术在临床实践中的应用，为早期识别耐药风险、优化个体化治疗策略提供了关键依据。

---

## 36. 解读瑞博西利在早期乳腺癌治疗中的局限：NATALEE试验引发的思考

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40562232](https://pubmed.ncbi.nlm.nih.gov/40562232)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40562232
**DOI：** 10.1016/j.annonc.2025.06.009

### 第一部分 原文与翻译

**英文原标题：** Navigating the limits of ribociclib in early breast cancer: questions from the NATALEE trial.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文似乎是一篇针对关键性NATALEE临床试验的深度评论或观点文章。其核心目的并非报告新数据，而是基于该试验结果，深入探讨瑞博西利在早期乳腺癌辅助治疗中的应用边界与尚存疑问。文章可能聚焦于患者的精准筛选、最佳治疗周期以及长期安全性等关键问题，旨在引导临床医生更审慎地解读与应用NATALEE试验的证据。此类分析对于推动个体化治疗策略的完善和指导未来研究方向具有重要的学术价值。

---

## 37. 重新思考瑞波西利：再探NATALEE试验中的剂量、疗程及N0高危困境

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40543843](https://pubmed.ncbi.nlm.nih.gov/40543843)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40543843
**DOI：** 10.1016/j.annonc.2025.06.012

### 第一部分 原文与翻译

**英文原标题：** Rethinking ribociclib: revisiting dosing, duration, and the N0 high-risk dilemma in the NATALEE trial.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

根据标题判断，本文可能是一篇针对关键性NATALEE临床试验的深度评述或社论。文章聚焦于瑞波西利（ribociclib）在该试验中的三大核心议题：给药剂量、治疗时长以及淋巴结阴性（N0）高危患者的治疗困境。通过对这些临床实践中关键问题进行再探讨，本文旨在推动学界对现有治疗方案的优化思考，为早期乳腺癌辅助治疗的个体化决策提供重要见解，具有较强的临床指导意义。

---

速递结束，祝您工作愉快！